



Clinical Trials on Alzheimer's Disease

Preliminary program



In-Person



Remote

October 29 - November 1, 2024
Madrid, Spain

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11 / Monte Carlo '12
San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18
San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22 / Boston '23

www.ctad-alzheimer.com

Email: ctad@ant-congres.com



SUMMARY

Organizing & Scientific Committees

3

Lifetime Achievement Award

4

Keynotes

5

Onsite Program

8

Tuesday, October 29

9

Wednesday, October 30

10

Thursday, October 31

13

Friday, November 1

15

Poster presentations

18

Congress Venue

43



Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Laura D. BAKER (Winston-Salem, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Lucia CRIVELLI (Buenos Aires, Brazil); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, USA); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Miia KIVIPETO (Stockholm, Sweden); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S. RAFFI (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Sietske SIKKES (Amsterdam, NL); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Heather SNYDER (Chicago, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Duygu TOSUN (San Francisco, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Prashanthi VEMURI (Rochester, USA); Michael W. WEINER* (San Francisco, USA); Donna M. WILCOCK (Indianapolis, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2024

Lifetime Achievement Award



This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Lars Lannfelt MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development.

Lars Lannfelt, MD, PhD
Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the "Swedish" mutation. This genetic mutation causes Alzheimer's disease in a large family and leads to 3-5 times increased production of amyloid β ($A\beta$). Another major scientific breakthrough was the detection of the "Arctic" mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated $A\beta$, protofibrils. These species of $A\beta$ are toxic. This inspired him to target $A\beta$ protofibrils with immunotherapy and they developed an antibody selective for $A\beta$ protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met.

He was awarded the Bengt Winblad's prize for increased understanding of the pathogenesis of Alzheimer's disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbal Lifetime Achievement Award in Alzheimer's Disease Research and the Swedish Alzheimer's Foundation (Alzheimerfonden) Grand Research Prize (2019).

Keynotes



“Next Generation of Clinical Trials for Alzheimer’s Disease and Related Disorders”

Catherine Mummerly, MD, PhD

Neurologist, Head of Clinical Trials, Dementia Research Center, University College London, London (United Kingdom)

Cath Mummerly is a consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London, and Deputy Director for the Leonard Wolfson Experimental Neurology Centre. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer’s disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a program of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer’s, but that we can deliver them promptly, safely and equitably.



“Lecanemab: from a mutation to a treatment for Alzheimer’s disease”

Lars Lannfelt, MD, PhD

Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the “Swedish” mutation. This genetic mutation causes Alzheimer’s disease in a large family and leads to 3-5 times increased production of amyloid β ($A\beta$). Another major scientific breakthrough was the detection of the “Arctic” mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated $A\beta$, protofibrils. These species of $A\beta$ are toxic. This inspired him to target $A\beta$ protofibrils with immunotherapy and they developed an antibody selective for $A\beta$ protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met. He was awarded the Bengt Winblad’s prize for increased understanding of the pathogenesis of Alzheimer’s disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research and the Swedish Alzheimer’s Foundation (Alzheimerfonden) Grand Research Prize (2019).



“Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?”

Rachelle Doodu, MD, PhD

Houston, TX (USA)

Rachelle Doodu is a distinguished neurodegeneration expert with a profound commitment to advancing treatments for neurodegenerative diseases. Extensive industry, clinical and academic medicine experience have shaped her views of personalized care and meaningful outcomes for patients. As the Global Head of Neurodegeneration and Alzheimer's disease and Neurodegeneration Franchise Head at Roche Pharmaceuticals and the US affiliate, Genentech (2016-Feb. 2024), she successfully created and led late-stage development programs for Alzheimer's, Parkinson's, and Huntington's diseases, aiming to provide comprehensive solutions from diagnostics to therapeutics. Board certified in Neurology and Psychiatry, Dr. Doodu trained at Baylor College of Medicine in Houston, Texas and McGill University in Montreal. While at Baylor College of Medicine, she founded and directed the Alzheimer's Disease and Memory Disorders Center and was the Effie Marie Cain Chair in AD Research. She also holds an MA/PhD in cognitive anthropology from Rice University. Dr. Doodu has served on steering committees for the National Institutes of Health-funded Alzheimer's Disease Cooperative Study and Alzheimer's Disease Neuroimaging Initiative, and the executive committee for the Alzheimer's Therapeutic Research Institute. Dr. Doodu was the Principal Investigator for the Phase 2 and 3 development of donepezil (Aricept), the most widely-used AD therapy globally, and contributed to the development of most of the other approved AD treatments as well as several under development. For over 30 years, Dr. Doodu has worked with biotech and pharma companies in the design and execution of trials for cognitive and behavioral treatment of AD. She has contributed to efforts to globalize approaches to AD, advising on guidelines in China, Malaysia, South Korea and the Philippines, and educating investigators throughout Europe and Asia on study design and outcome measures to support global studies. Dr. Doodu has published over 235 original articles in this field, has been awarded with a Lifetime Achievement Award by the Clinical Trials in Alzheimer's Disease group in 2018, and is Immediate Past-Chair of the US Alzheimer's Association Research Roundtable. She is a Distinguished Alumna from Rice University and Distinguished Faculty Award winner from Baylor College of Medicine.



“Fluid biomarkers in research, clinical trials, and clinical practice”

Suzanne E. Schindler MD, PhD

Associate Professor of Neurology, Washington University School of Medicine, St. Louis, MO (USA)

Dr. Suzanne Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E metabolism. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia. Currently Dr. Schindler sees patients with memory concerns and coordinates biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center. She received a large R01 to evaluate novel fluid biomarkers. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

ONSITE PROGRAM

in Madrid

Available via livestream
on the CTAD24
digital platform

Demographics and baseline disease

Amyloid PET SUVR, mean composite $\pm$ SD	
Age in years, mean $\pm$ SD	
Female, n (%)	
ApoE ϵ 4, n (%)	
Carrier	
Non-carrier	
Clinical stage, n (%)	
MCI due to AD	
Mild AD	
CDR-SB score, mean $\pm$ SD	
MMSE score, mean $\pm$ SD	
ADAS-Cog13 score, mean $\pm$ SD	
ADCS-ADL-MCI score, mean $\pm$ SD	

Patients that reached amyloid plaque negative status at Week

- Lower baseline amyloid burden
- A higher proportion of ApoE ϵ 4 noncarriers; this finding is a protocol amendments^b

Program at a glance

● Tuesday, OCTOBER 29

- 2.45 p.m. POSTER WALKING TOUR
- 3.15 p.m. TAKING CARE – A movie
- 4.00 p.m. Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research
- 4.30 p.m. KEYNOTE 1: Lecanemab: from a mutation to a treatment for Alzheimer's disease
- 4.55 p.m. ORAL COMMUNICATIONS
- 6.10 p.m. LATE BREAKING SYMPOSIUM
- 6.50 p.m. CTAD Networking Event with the Support of the Alzheimer's Association

● Wednesday, OCTOBER 30

- 7.15 a.m. POSTER WALKING TOUR
- 8.15 a.m. LATE BREAKING COMMUNICATIONS
- 9.00 a.m. KEYNOTE 2: Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders
- 9.25 a.m. SYMPOSIUM 1: Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?
- 10.05 a.m. Coffee break and poster session
- 10.35 a.m. LATE BREAKING COMMUNICATIONS
- 11.20 a.m. ORAL COMMUNICATIONS
- 12.20 p.m. Lunch and poster sessions
- 1.20 p.m. ROUNDTABLE: Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments
- 2.00 p.m. ORAL COMMUNICATIONS
- 3.15 p.m. LATE BREAKING COMMUNICATIONS
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. ORAL COMMUNICATIONS

● Thursday, OCTOBER 31

- 7.15 a.m. POSTER WALKING TOUR
- 8.15 a.m. LATE BREAKING COMMUNICATIONS
- 9.30 a.m. KEYNOTE 3: Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?
- 9.55 a.m. ORAL COMMUNICATIONS
- 10.40 a.m. Coffee break and poster session
- 11.10 a.m. ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease
- 11.40 a.m. LATE BREAKING COMMUNICATIONS
- 12.40 p.m. Lunch and poster sessions
- 1.40 p.m. KEYNOTE 4: Fluid biomarkers in research, clinical trials, and clinical practice
- 2.05 p.m. ORAL COMMUNICATIONS
- 2.50 p.m. LATE BREAKING COMMUNICATIONS
- 3.50 p.m. Coffee break and poster session
- 4.20 p.m. ORAL COMMUNICATIONS

● Friday, NOVEMBER 1

- 7.15 a.m. POSTER WALKING TOUR
- 8.15 a.m. LATE BREAKING COMMUNICATIONS
- 9.30 a.m. ORAL COMMUNICATIONS
- 10.30 a.m. Coffee break and poster session
- 11.00 a.m. LATE BREAKING ORAL COMMUNICATIONS
- 12.05 p.m. LATE BREAKING ROUNDTABLE
- 12.35 p.m. Lunch and poster sessions
- 1.30 p.m. LATE BREAKING SYMPOSIUM
- 2.10 p.m. ORAL COMMUNICATIONS
- 3.10 p.m. Coffee break and poster session
- 3.45 p.m. LATE BREAKING ORAL COMMUNICATIONS

● Tuesday,
OCTOBER 29



2.45-3.15 p.m. **POSTER WALKING TOUR**

3.15 p.m. **TAKING CARE – A movie**

Directed and produced by award-winning filmmaker James Keach, and produced by Seth Rogen and Lauren Miller Rogen. This 40-minute documentary featuring the story of Lauren and Seth's courtship and marriage as their family faces the complexities and heartbreak of Lauren's mother's advancing early-onset Alzheimer's disease.

4.00 p.m. **Welcome ceremony and CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research**

Presented to Lars Lannfelt, MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development
Introduction by the CTAD Organizing Committee

4.30 p.m. **KEYNOTE 1**

Lecanemab: from a mutation to a treatment for Alzheimer's disease

Lars Lannfelt, Uppsala University, Uppsala (Sweden)

4.55 p.m. **ORAL COMMUNICATIONS**

4.55 p.m. **OC1 - Understanding ARIA risk in Adults with Early Symptomatic Alzheimer's Disease: Primary Results from TRAILBLAZER-ALZ 6**

Hong Wang¹, Emel Serap Nery¹, Paul Ardayfio¹, Dunlei Cheng¹, Rashna Khanna¹, Paula Hauck¹, Dawn Brooks¹, Emily Collins¹, John Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

5.10 p.m. **OC2 - Fosgonimeton in Mild-to-Moderate Alzheimer's Disease: Topline Efficacy and Safety Results from the LIFT-AD Trial**

Kevin Church¹, Hans Moebius², Len Walt³, Javier San Martin¹, Michael Hale¹, Anton Porsteinsson⁴, Simon Daggett¹

¹Athira Pharma - Bothell (United States), ²moebius-consult GmbH - Baar (Switzerland), ³SSI Strategy - Toronto (Canada), ⁴University of Rochester - Rochester (United States)

5.25 p.m. **OC3 - Immunometabolic and Vascular Modulators for Combination Therapy in AD: Results of a Phase II Trial of Intranasal Insulin and the SGLT2 Inhibitor Empagliflozin**

Jennifer Erichsen¹, Thomas Register¹, Courtney Sutphen¹, James R. Bateman¹, Melissa Rundle¹, Marc Rudolph¹, Samuel Lockhart¹, Suzanne Craft¹

¹Wake Forest School of Medicine - Winston-Salem (United States)

5.40 p.m. **OC4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD**

Kristin Wildsmith¹, Kanta Horie^{1,2}, Arnaud Charil¹, Nicolas Barthelemy², David Verbel¹, Anthonin Reihac-laborde¹, Brian Gordon², Peter Boyd³, Robert Bell¹, Sumit Rawal¹, Erica Andreozzi¹, Tammie Benzinger², Randall Bateman², Jin Zhou¹, Larisa Reyderman¹

¹Eisai Inc. - Nutley (United States), ²Washington University School of Medicine - St Louis (United States), ³Eisai Europe Ltd. - Hatfield (United Kingdom)

5.55 p.m. **OC5 - Results from COGO201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease**

Michael Woodward¹, Everard Vijverberg^{2,3}, Susan Catalano⁴, Theresa Devins⁵, Valentina Di Caro⁵, Michael Grundman⁶, Mary Hamby⁵, Jennifer Iaci⁵, Anthony Caggiano⁵

¹Austin Health - Melbourne, Victoria (Australia), ²Brain Research Center - Amsterdam (Netherlands), ³UMC - Amsterdam (Netherlands), ⁴Capsida Therapeutics - Thousand Oaks (United States), ⁵Cognition Therapeutics, Inc., New York (United States), ⁶Global R&D Partners, LLC - La Jolla (United States)

6.10 p.m. **Late breaking Symposium**

6.50 - 7.50 p.m. **CTAD Networking Event with the Support of the Alzheimer's Association**

● Wednesday, OCTOBER 30

7.15 a.m. POSTER WALKING TOUR

8.15 a.m. LATE BREAKING COMMUNICATIONS

9.00 a.m. KEYNOTE 2

Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders

Catherine Mummery, *Dementia Research Center, University College London, London (United Kingdom)*

9.25 a.m. SYMPOSIUM 1

Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?

Chair: Christopher van Dyck, Yale University, New Haven (United States)

Presentation 1: Mechanistic Rationale for Continued Lecanemab Dosing

Michael Irizarry, *Eisai Inc. - Nutley (United States)*

Presentation 2: Pharmacologic Support for a Maintenance Dosing Regimen with Lecanemab: An Update on the Latest Clinical Pharmacology Data and Modeling

Larisa Reyderman, *Eisai Inc. - Nutley (United States)*

Presentation 3: Evidence for a Continued Benefit for Long-Term Lecanemab Treatment: A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data

Christopher van Dyck, *Yale University, New Haven (United States)*

10.05 a.m. Coffee break and poster session ☕

10.35 a.m. LATE BREAKING COMMUNICATIONS

11.20 a.m. ORAL COMMUNICATIONS

11.20 a.m. **OC6 - Screening and baseline results from the donanemab preclinical Alzheimer's disease TRAILBLAZER-ALZ 3 study**

Karen C Holdridge¹

¹*Eli Lilly and Company - Indianapolis (United States)*

11.35 a.m. **OC7 - Results from the Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) Study**

Hamid Okhravi¹, Sheriza Baksh², Emily Clark³

¹*Goldrich Neurohealth Institute, Eastern Virginia Medical School - Norfolk (United States)*, ²*Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health - Baltimore (United States)*, ³*Department of Psychiatry, University of Rochester School of Medicine and Dentistry - Rochester (United States)*

11.50 a.m. **OC8 - Differences in Amyloid PET Results and Social Determinants of Health by Race/Ethnicity: Results from New IDEAS**

Gil Rabinovici^{1,2}, Peggye Dilworth-Anderson², Lucy Hanna³, Jon Steingrimsdottir³, Ilana Gareen³, Emily Glavin⁴, Bruce Hillner⁵, Andrew March⁴, Barry Siegel⁶, Christopher Weber⁷, Charles Windon¹, Rachel Whitmer⁸, Constantine Gatsonis³, Maria Carrillo⁷, Consuelo Wilkins⁹

¹*University of California San Francisco - San Francisco (United States)*, ²*University of North Carolina - Chapel Hill (United States)*, ³*Brown University - Providence (United States)*, ⁴*American College of Radiology - Reston (United States)*, ⁵*Virginia Commonwealth University - Richmond (United States)*, ⁶*Washington University - St. Louis (United States)*, ⁷*Alzheimer's Association - Chicago (United States)*, ⁸*University of California Davis - Sacramento (United States)*, ⁹*Vanderbilt University - Nashville (United States)*

12.05 p.m. **OC9 - First results from the REAL AD study: Validation of a realistic screening approach for early Alzheimer's disease**

Kaj Blennow^{1,2}, Silke Kern^{1,2}, Iris Bosch², Henrik Zetterberg^{1,3,4,2}, Michael Schöll^{1,3,2}

¹*University of Gothenburg - Gothenburg (Sweden)*, ²*Västra Götaland Region - Gothenburg (Sweden)*, ³*University College London - London (United Kingdom)*, ⁴*University of Wisconsin-Madison (United States)*

● Wednesday, OCTOBER 30



12.20 p.m. Lunch and poster session

1.20 p.m. ROUNDTABLE

Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments

Howard Fillit¹, Jeffrey Cummings², Michael Gold³, Suzzane Hendrix⁴, Michael Irizarry⁵, Maria Tome⁶

¹Alzheimer's Drug Discovery Foundation - New York (United States), ²UNLV - Nevada, Las Vegas (United States), ³Compass Pathways - New York (United States), ⁴Pentara - Salt Lake City (United States), ⁵Eisai - Nutley (United States), ⁶European Medical Agency - Rome (Italy)

2.00 p.m. ORAL COMMUNICATIONS

2.00 p.m. **OC10 - PROSPECT-ALZ: A Phase 2 study of LY3372689, an orally available O-linked N-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer's disease**

Adam Fleisher¹, Mirosław Brys¹

¹Eli Lilly and Company - Indianapolis (United States)

2.15 p.m. **OC11 - Biomarkers of neurodegeneration and synaptic dysfunction differentiate cognitively unimpaired individuals with high levels of Alzheimer's disease (AD) neuropathology from individuals with AD dementia**

Sara Fernandes-Taylor¹, Matthew Glittenberg¹, Ira Frahm², Brianne Breidenbach¹, Tobey Betthausen¹, Sanjay Asthana¹, Sterling Johnson¹, Gwendlyn Kollmorgen², Clara Quijano-Rubio³, Henrik Zetterberg⁴, Kaj Blennow⁴, Ozioma Okonkwo¹

¹University of Wisconsin - Madison (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³Roche Diagnostics International Ltd. - Rotkreuz (Switzerland), ⁴Neurochemistry Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg - Goteborg (Sweden)

2.30 p.m. **OC12 - Study Design and Screening Experience from the Phase 2 AUTONOMY Trial of Anti-P-tau Monoclonal Antibody Posdinemab for Early Alzheimer's Disease**

Dave Henley^{1,2}, Jennifer Bogert³, Ziad S Saad⁴, Gallen Triana-Baltzer⁴, Tina Wang⁴, Hartmuth C Kolb⁴, Maggie Fedgchin¹

¹Janssen Research & Development, LLC - Titusville (United States), ²Indiana University School of Medicine, Psychiatry - Indianapolis (United States), ³Janssen Research & Development, LLC - Bridgewater (United States), ⁴Janssen Research & Development, LLC - La Jolla (United States)

2.45 p.m. **OC13 - Performance of plasma p-tau217 in an African American cohort: Findings from the African Americans Fighting Alzheimer's in Midlife study**

Gilda Ennis¹, Derek Norton¹, Fabu Carter¹, Diane Gooding¹, Alexander Gee², Tracy Smith¹, Hector Salazar¹, Rachael Wilson¹, Rebecca Langhough¹, Megan Zuelsdorff¹, Shenikqua Bouges¹, Sanjay Asthana¹, Sterling Johnson¹, Henrik Zetterberg¹, Carey Gleason¹

¹University of Wisconsin-Madison - Madison (United States), ²Nehemiah Center for Urban Leadership Development - Madison (United States)

3.00 p.m. **OC14 - Early increase of the synaptic blood marker β -synuclein in asymptomatic individuals with autosomal dominant Alzheimer's disease**

Patrick Oeckl^{1,2}, Randall J. Bateman³, Gregory S. Day⁴, Nick C. Fox⁵, Laura Ibanez³, Mathias Jucker^{6,7}, Jae-Hong Lee⁸, Johannes Levin^{9,10,11}, Jorge J. Llibre-Guerra³, Eric Mc Dade³, John C. Morris³, Jee Hoon Roh¹², Raquel Sánchez-Valle¹³, Peter R. Schofield¹⁴, Markus Otto¹⁶

¹Ulm University Hospital- Ulm (Germany), ²DZNE Ulm - Ulm (Germany), ³Washington University School of Medicine - Saint Louis (United States), ⁴Mayo Clinic in Florida - Jacksonville (United States), ⁵UCL Queen Square Institute of Neurology - London (United Kingdom), ⁶DZNE Tübingen - Tübingen (Germany), ⁷University of Tübingen - Tübingen (Germany), ⁸Asan Medical Center - Seoul (Korea, Republic of), ⁹LMU Munich - Munich (Germany), ¹⁰DZNE Munich - Munich (Germany), ¹¹Munich Cluster for Systems Neurology (SyNergy) - Munich (Germany), ¹²Korea University College of Medicine - Seoul (Korea, Republic of), ¹³University of Barcelona - Barcelona (Spain), ¹⁴Neuroscience Research Australia - Sydney (Australia), ¹⁵University of New South Wales - Sydney (Australia), ¹⁶Martin-Luther-University Halle-Wittenberg - Halle (saale) (Germany)

3.15 p.m. LATE BREAKING COMMUNICATIONS

3.45 p.m. Coffee break and poster session



● Wednesday, OCTOBER 30

4.15 p.m. ORAL COMMUNICATIONS

4.15 p.m. OC15 - Advancing Patient Outcomes with Real-World Evidence

Ann Hartry¹, Helmut Butzkueven^{2,3}, Robert Perneczky⁴, Craig Ritchie⁵

¹Eli Lilly and Company - Indianapolis (United States), ²MSBase Foundation - Melbourne (Australia), ³Monash University - Melbourne (Australia), ⁴Ludwig-Maximilians-Universität Munich - Munich (Germany), ⁵University of St. Andrews - St. Andrews (United Kingdom)

4.30 p.m. OC16 - Longitudinal trajectories of plasma p-tau217 in early Alzheimer's Disease: Implications for use in clinical trials

Bjørn-Eivind Kirsebom¹, Fernando Gonzalez-Ortiz², Lene Pålhaugen³, Per Selnes³, Jonas Alexander Jarholm³, Berglind Gísladóttir³, Arvid Rongve⁴, Ragnhild Eide Skogseth⁵, Geir Bråthen⁶, Dag Aarsland⁷, Michael Turton⁸, Peter Harrison⁸, Henrik Zetterberg², Kaj Blennow², Tormos Fladby³

¹University Hospital of North Norway - Tromsø (Norway), ²University of Gothenburg - Gothenburg (Sweden), ³Akershus University Hospital - Lørenskog (Norway), ⁴Helse Fonna - Haugesund (Norway), ⁵Haraldsplass Deaconess Hospital - Bergen (Norway), ⁶University Hospital of Trondheim - Trondheim (Norway), ⁷King's College London - London (United Kingdom), ⁸Bioventix Plc - Surrey (United Kingdom)

4.45 p.m. OC17 - Precision Neuroscience: Rationale And Design For The REtAIN Phase 2b Study With A Tau Active Immunotherapy In Preclinical Alzheimer's Disease

Lennert Steukers¹, Iva Kezic¹, Cathy Bleys¹, Lingjue Li², Clara Theunis¹, Athena Beckers¹, Gallen Triana-Baltzer³, Tricia Thornton-Wells⁴, TAU PE³, David Henley², Fiona Elwood⁴, María Cristina López López⁵

¹Johnson & Johnson - Beerse (Belgium), ²Johnson & Johnson - Titusville (United States), ³Johnson & Johnson - La Jolla (United States), ⁴Johnson & Johnson - Cambridge (United States), ⁵Johnson & Johnson - Allschwil (Switzerland)

5.00 p.m. OC18 - Blood biomarkers to detect Alzheimer's disease in clinical practice – a cross-sectional study in primary and secondary care

Sebastian Palmqvist¹, Pontus Tideman¹, Niklas Mattsson-Carlgrén¹, Ruben Smith¹, Rik Ossenkoppele¹, Suzanne Schindler², Mark Monane³, Tim West³, Kaj Blennow⁴, Philip Verghese³, Joel Braunstein³, Shorena Janelidze¹, Erik Stomrud¹, Gemma Salvadó¹, Oskar Hansson¹

¹Lund University - Malmö (Sweden), ²Washington University School of Medicine - Saint Louis (United States), ³C2N Diagnostics - Saint Louis (United States), ⁴Gothenburg University - Gothenburg (Sweden)

5.15 p.m. OC19 - Plasma P-tau217 assays in clinical practice: Current uses and the future of Alzheimer's disease diagnosis

Jim Hendrix¹, Marc Suarez-Calvet², Joel Braunstein³, Rose Beck⁴, Manu Vandijck⁵, Rebecca Edelmayer⁶, Marwan Sabbagh⁷, Jonathan Schott⁸

¹Eli Lilly and Company - Indianapolis (United States), ²BarcelonaBeta Brain Research Center - Barcelona (Spain), ³C2N Diagnostics - Saint Louis (United States), ⁴Eli Lilly Clinical Diagnostics Laboratory - Indianapolis (United States), ⁵Fujirebio Europe N.V. - Gent (Belgium), ⁶Alzheimer's Association - Chicago (United States), ⁷Barrow Neurological Institute - Phoenix (United States), ⁸University College London - London (United Kingdom)

● Thursday, OCTOBER 31



7.15 a.m. POSTER WALKING TOUR

8.15 a.m. LATE BREAKING COMMUNICATIONS

9.30 a.m. **KEYNOTE 3**
Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?
Rachelle Doody, Houston, TX (USA)

9.55 a.m. ORAL COMMUNICATIONS

9.55 a.m. **OC20 - Initial results from remote speech-based screening in the first 900 digitally recruited participants in ADNI-4**
Caroline Skirrow¹, Jack Weston¹, Melanie J. Miller^{2,3}, Rachel L. Nosheny^{2,4}, Bruce Albala^{5,6}, Michael W. Weiner^{2,3,4}, Emil Fristed¹
¹Novoic Ltd - London (United Kingdom), ²Northern California Institute for Research and Education (NCIRE) - San Francisco (United States),
³Department of Veterans Affairs Medical Center - San Francisco (United States), ⁴University of California, San Francisco - San Francisco (United States), ⁵University of California Irvine - Irvine (United States), ⁶Veterans Administration Long Beach Healthcare System - Long Beach (United States)

10.10 a.m. **OC21 - Validating speech-based biomarkers for measuring disease progression in AD: A head-to-head comparison of three biomarker development strategies**
Michael Spilka¹, Mengdan Xu¹, Bali Toth², Somaye Hashemifar², Rainier Amora², Jessica Robin¹, Edmond Teng², Cecilia Monteiro², William Simpson¹
¹Winterlight Labs (Cambridge Cognition) - Toronto (Canada), ²Genentech, Inc. - South San Francisco (United States)

10.25 a.m. **OC22 - Eligibility for anti-amyloid treatment in real world memory clinic populations**
Anna Matton^{1,2}, Makrina Daniilidou^{1,2}, Anette Hall^{3,1}, Ulf Öhlund-Wistbacka^{4,1}, Urban Ekman¹, Anna Rennie¹, Linus Jönsson¹, Göran Hagman⁴, Alina Solomon^{3,1}, Anna Rosenberg^{3,1}, Miia Kivipelto^{4,1,2}
¹Karolinska Institutet - Stockholm (Sweden), ²FINGERS Brain Health Institute - Stockholm (Sweden), ³University of Eastern Finland - Kuopio (Finland), ⁴Karolinska University Hospital - Stockholm (Sweden)

10.40 a.m. Coffee break and poster session ☕

11.10 a.m. **ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease**
Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (USA)

11.10 a.m. **OC23 - Transcranial Magnetic Stimulation (TMS) for MCI: Trials using advanced stimulation and precision approaches**
Joy Taylor¹, Ying-Hui Chou², Andreana Benitez³
¹Stanford University - Palo Alto (United States), ²University of Arizona - Tucson (United States), ³Medical University of South Carolina - Charleston (United States)

11.25 a.m. **OC24 - Results of a 52-Week Phase II Trial of Repetitive TMS of the Default Mode Network in Mild to Moderate Alzheimer's Disease**
Elias Casula¹, Sonia Bonni¹, Michele Maiella¹, Martina Assogna¹, Emiliano Santarnecchi², Alessandro Martorana³, Giacomo Koch³
¹Santa Lucia Foundation IRCCS - Rome (Italy), ²Massachusetts General Hospital - Boston (United States), ³University of Rome Tor Vergata - Rome (Italy)

11.40 a.m. LATE BREAKING COMMUNICATIONS

12.40 p.m. Lunch and poster session

1.40 p.m. **KEYNOTE 4**
Fluid biomarkers in research, clinical trials, and clinical practice
Suzanne Schindler, Washington University in St. Louis - St. Louis (United States)

● Thursday, OCTOBER 31

2.05 p.m.

ORAL COMMUNICATIONS

2.05 p.m.

OC25 - TargetTau-1: A phase 2 trial designed to evaluate the efficacy, safety, and tolerability of the anti-MTBR tau monoclonal antibody, BMS-986446, in patients with early Alzheimer's disease

Oskar Hansson ¹, Anja Kahl ², Grigor Abelian ², Mark Donovan ², Manuj Ahuja ², David Watson ³, Rik Ossenkoppele ⁴, Takeshi Iwatsubo ⁵, Christopher Van Dyck ⁶

¹Lund University and Skåne University Hospital - Malmö (Sweden), ²Bristol Myers Squibb, Princeton (United States), ³Alzheimer's Research and Treatment Center, Wellington (United States), ⁴Lund University, Skåne University Hospital - Malmö (Sweden), ⁵University of Tokyo - Tokyo (Japan), ⁶Yale School of Medicine, New Haven (United States)

2.20 p.m.

OC26 - A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory imaging applied to the Bio-Hermes Trial

Richard Joules ¹, Robin Wolz ¹, Lynne Hughes ^{1,2}, Richard Mohs ², John Dwyer ², Douglas Beauregard ²

¹IXICO - London (United Kingdom), ²Global Alzheimer's Platform Foundation - Washington (United States)

2.35 p.m.

OC27 - Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, SEMA4D antibody to block reactive astrogliosis, in patients with mild AD dementia

Elizabeth Evans ¹, Eric Siemers ¹, Terrence Fisher ¹, Megan Boise ¹, Amber Foster ¹, John Leonard ¹, Vikas Mishra ¹, Crystal Mallow ¹, Raymond Turner ², John Huffaker ³, Anton Porsteinsson ⁴, Maurice Zauderer ¹

¹Vaccinex - Rochester (United States), ²Georgetown University - Washington (United States), ³Neuropsychiatric Research Center of Southwest Florida - Stuart (United States), ⁴University of Rochester - Rochester (United States)

2.50 p.m.

LATE BREAKING COMMUNICATIONS

3.50 p.m.

Coffee break and poster session



4.20 p.m.

ORAL COMMUNICATIONS

4.20 p.m.

OC28 - Design and Rationale of cAPPricorn-1, A Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy

Jin-Moo Lee ¹, Ellis S. Van Etten ², M. J. P. Van Osch ², Catharina J. M. Klijn ³, Alexandre Sostelly ⁴, Sasikiran Goteti ⁴, Farshid Sepehrband ⁵, Andreja Avbersek ⁵, Robert W. Deering ⁴, Neal S. Parikh ⁴, Steven M. Greenberg ⁶

¹Washington University School of Medicine - St. Louis (United States), ²Leiden University Medical Center - Leiden (Netherlands), ³Radboud University Medical Centre - Nijmegen (Netherlands), ⁴Alnylam Pharmaceuticals, Inc. - Cambridge (United States), ⁵Regeneron Pharmaceuticals, Inc. - Tarrytown (United States), ⁶Harvard Medical School, Massachusetts General Hospital - Boston (United States)

4.35 p.m.

OC29 - Use of plasma p-tau217 to identify Aβ-positive cognitively unimpaired participants for clinical trials: A multicohort study

Gemma Salvadó ¹, Shoren Janelidze ¹, Divya Bali ¹, Joseph Theriault ², Tammie L.s. Benzinger ³, Kaj Blennow ⁴, Pedro Rosa-Neto ⁵, Sterling C Johnson ⁶, Christopher C Rowe ⁷, Sylvia Villeneuve ⁸, Cliff R Jack Jr. ⁹, Marc Suárez-Calvet ¹⁰, Suzanne E Schindler ³, Rik Ossenkoppele ^{1,11}, Oskar Hansson ¹

¹Lund University - Lund (Sweden), ²McGill University - Montréal (Canada), ³Washington University School of Medicine and Knight Alzheimer Disease Research Center - St. Louis (United States), ⁴Sahlgrenska University Hospital - Mölndal and University of Gothenburg - Gothenburg (Sweden), ⁵McGill University - Montréal (Canada), ⁶University of Wisconsin-Madison and Wisconsin Alzheimer's Institute - Madison (United States), ⁷CSIRO Health and Biosecurity- Victoria and Austin Health - Melbourne (Australia), ⁸Douglas Mental Health University Institute - Montréal (Canada), ⁹Mayo Clinic and Foundation - Rochester (United States), ¹⁰BarcelonaBeta Brain Research Center and Hospital del Mar Research Institute - Barcelona (Spain), ¹¹UMC and Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

4.50 p.m.

OC30 - PreventE4: a double-blind placebo-controlled clinical trial testing high dose DHA in APOE4 carriers before the onset of dementia

Hussein Yassine ¹, Michael Harrington ¹, Jackson Park ¹, Isabella Cordova ¹, Naoko Kono ¹, Wendy Mack ¹, Meredith Braskie ¹, Lon Schneider ¹

¹USC - Los Angeles (United States)

● Friday, NOVEMBER 1



7.15 a.m. POSTER WALKING TOUR

8.15 a.m. LATE BREAKING COMMUNICATIONS

9.30 a.m. ORAL COMMUNICATIONS

9.30 a.m. **OC31 - The Alzheimer's Tau Platform (ATP) and Progressive Supranuclear Palsy Trial Platform (PTP): a combination amyloid and tau therapy trial for early AD, and a tau monotherapy trial for mild-moderate PSP**

Adam Boxer¹, Keith Johnson², Irene Litvan³, Julio Rojas¹, Anne-Marie Wills², Reisa Sperling², Paul Aisen⁴, Ron Petersen⁵, Randall Bateman⁶, Chihiro Sato⁶, Michael Donohue⁴, Rema Raman⁴, Eden Barragan³

¹University of California, San Francisco - San Francisco (United States), ²MGH - Boston (United States), ³UCSD - San Diego (United States), ⁴USC - San Diego (United States), ⁵Mayo Clinic - Rochester (United States), ⁶Washington University - St. Louis (United States)

9.45 a.m. **OC32 - An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study**

Joel Braunstein¹, Demetrius Maraganore², Robert Carlile³, Kim Johnson⁴, David Merrill⁵, Darren Gitelman⁶, Kenneth Sharlin⁷, Lawren Vandevrede⁸, Kristi George⁹, Jimin Wang¹⁰, Tim West¹, Philip Verghese¹, Leslie Jacobs¹, Mark Monane¹

¹C2N Diagnostics, LLC - St Louis (United States), ²Tulane University - New Orleans (United States), ³Palmetto Primary Care Physicians - Summerville (United States), ⁴Duke University - Durham (United States), ⁵Pacific Brain Health Center - Santa Monica (United States), ⁶Advocate Lutheran General Hospital - Park Ridge (United States), ⁷Sharlin Health and Neurology - Ozark (United States), ⁸University of California - San Francisco (United States), ⁹JWM Neurology - Indianapolis (United States), ¹⁰Stat4ward - Pittsburgh (United States)

10.00 a.m. **OC33 - The role of trials in health-economic evaluation of anti-amyloid treatment for early Alzheimer's disease**

Ron Handels¹, Anders Wimo², Bengt Winblad², Linus Jönsson²

¹Maastricht University - Maastricht (Netherlands), ²Karolinska Institutet - Stockholm (Sweden)

10.30 a.m. Coffee break and poster session 

11.00 a.m. LATE BREAKING ORAL COMMUNICATIONS

12.05 p.m. LATE BREAKING ROUNDTABLE

12.35 p.m. Lunch break and poster sessions

1.30 p.m. LATE BREAKING SYMPOSIUM

2.10 p.m. ORAL COMMUNICATIONS

2.10 p.m. **OC35 - Anti-amyloid antibody preference for vascular Aβ aggregates does not explain ARIA rates**

Anna Francis¹, Angela Meunier¹, Amirah Anderson¹, Elizabeth Hennessey¹, Michael Miller¹, Cynthia Lemere¹, Dennis Selkoe¹, Andrew Stern¹

¹Brigham and Women's Hospital - Boston (United States)

2.25 p.m. **OC36 - Artificial Intelligence-enabled Safety Monitoring in Alzheimer's Disease Clinical Trials**

Gustavo Jimenez-Maggiora¹, Michael Donohue¹, Michael Rafii¹, Rema Raman¹, Paul Aisen¹

¹Keck School of Medicine of USC - San Diego (United States)

● Friday, NOVEMBER 1

2.40 p.m.

OC37 - First-in-human AV-1980R/A tau vaccine for Alzheimer's prevention (IND 29644)

Lon Schneider¹, Anahit Ghochikyan², Robert Alexander³, Duygu Tosun-Turgut⁴, Michael Agadjanyan²

¹Keck School of Medicine, University of Southern California - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴University of California, San Francisco - San Francisco (United States)

2.55 p.m.

OC38 - Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics: head-to-head comparison among an Asian population

Hyemin Jang¹, Daeun Shin², Heejin Yoo², Henrik Zetterberg^{3,4,5,6}, Kaj Blennow^{3,7,8,9}, Fernando Gonzalez-Ortiz^{3,4}, Nicholas J. Ashton^{3,10,11,12}, Theresa A. Day¹³, Eun Hye Lee², Jihwan Yun¹⁴, Duk L Na², Hee Jin Kim^{2,15,16}, Sung Hoon Kang¹⁷, Jun Pyo Kim², Sang Won Seo^{2,15,16}

¹National University College of Medicine - Seoul (Korea, Republic of), ²Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³University of Gothenburg - Gothenburg (Sweden), ⁴Sahlgrenska University Hospital, - Gothenburg (Sweden), ⁵UCL Institute of Neurology - London (United Kingdom), ⁶UK Dementia Research Institute - London (United Kingdom), ⁷Sahlgrenska University Hospital - Gothenburg (Sweden), ⁸ICM - Paris (France), ⁹First Affiliated Hospital of USTC - Hefei (China), ¹⁰King's College London - London (United Kingdom), ¹¹NIHR and NHS Foundation - London (United Kingdom), ¹²Stavanger University Hospital - Stavanger (Norway), ¹³Eli Lilly and Company - Indianapolis (United States), ¹⁴Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), ¹⁵Samsung Medical Center, - Seoul (Korea, Republic of), ¹⁶Sungkyunkwan University - Seoul (Korea, Republic of), ¹⁷Korea University College of Medicine - Seoul (Korea, Republic of)

3.10 p.m.

Coffee break and poster session



3.45 p.m.

LATE BREAKING COMMUNICATIONS



POSTER PRESENTATIONS
presented in Madrid
and available on the CTAD24
digital platform

CTAD24 POSTER LISTING

All posters are available in Pdf format
at all times on the CTAD24 digital platform.

Posters presented **remotely**
are indicated with this icon :



From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.

POSTER SESSION 1

THEME 01: Clinical Trials: Methodology	P001 to P020
THEME 02: Clinical Trials: Results	P021 to P040
THEME 11: New Therapies and Clinical Trials	P041 to P062
THEME 14: Beyond Amyloid and Tau	P063 to P075
THEME 15: Clinical Trials Early Career Investigator Showcase	P076 to P078

From Thursday, October 31 - 7:15 a.m. to 5:00 p.m.

POSTER SESSION 2

THEME 03: Clinical Trials: Imaging	P079 to P101
THEME 04: Clinical Trials: Biomarkers including plasma	P102 to P144
THEME 12: Proof of Concept/Translational research for AD Development interventions	P145 to P161
THEME 15: Clinical Trials Early Career Investigator Showcase	P162

From Friday, November 1 - 7:15 a.m. to 5:00 p.m.

POSTER SESSION 3

THEME 05: Clinical Trials: cognitive and functional endpoints	P163 to P177
THEME 06: Cognitive assessment and clinical trials	P178 to P201
THEME 07: Behavioral disorders and clinical trials	P202 to P205
THEME 08: Health economics and clinical trials	P206 to P209
THEME 09: Epidemiology and clinical trials	P210 to P220
THEME 10: Animal Model	P221 to P225
THEME 13: Digital health/E-trials	P226 to P249
THEME 15: Clinical Trials Early Career Investigator Showcase	P250 to P253



POSTER SESSION 1: From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.

THEME 01: Clinical Trials: Methodology

- P001 Screening for Cognitive Impairment across Four Different European Dementia Cohorts Using an Automatic Digital Cognitive Assessment**
Johannes Tröger¹, Elisa Mallick¹, Nicklas Linz¹, Gonzalo Sánchez Benavides², Inez Ramakers³, Silke Kern⁴, Ingmar Skoog⁴, Stefanie Köhler⁵, Stefan Teipel⁵, Alexandra König¹
¹ki elements GmbH - Saarbrücken (Germany), ²BarcelonaBeta Brain Research Center (BBRC), Hospital del Mar Research Institute - Barcelona (Spain), ³Maastricht University Medical Center (MUMC+) - Maastricht (Netherlands), ⁴Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden), ⁵Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) - Rostock (Germany)
- P002 Increasing statistical power of early Alzheimer's disease clinical trials with the AD-PxTM prognostic model**
Angela Tam¹, César Laurent¹, Christian Dansereau¹
¹Perceiv AI - Montreal (Canada)
- P003 Clinical Trials in Chronic Traumatic Encephalopathy: are we there yet?**
Charles Bernick¹, Guogen Shan², Dawn Matthews³, Aaron Ritter⁴
¹Cleveland Clinic - Las Vegas (United States), ²University of Florida - Gainesville (United States), ³ADMDx - Chicago (United States), ⁴Hoag Medical Center - Newport Beach (United States)
- P004 Storyteller as a Recruitment and Pre-Screening tool for Alzheimer's Disease Clinical Trials**
Sarah Hollingshead¹, Jeffrey Norton¹, Isabella Hernandez¹, Jack Weston², Emil Fristed², Caroline Skirrow²
¹Charter Research - The Villages (United States), ²Novoic Ltd - London (United Kingdom)
- P005 Novel pilot Phase 1 clinical trial with PV-1950R/A vaccine for Lewy Body Dementia (LBD)**
James Galvin¹, Michael Agadjanyan²
¹University of Miami Miller School of Medicine - Boca Raton (United States), ²Institute for Molecular Medicine - San Diego (United States)
- P006 Key stakeholder engagement and protocol development for the IHI-funded public-private partnership project PREDICTOM**
Zunera Khan¹, Anna-Katherine Brem¹, Ashworth Mark¹, Nick Ashton¹, Brandt Sigurd², Corbett Anne³, Pickering Ellie³, Diaz Ana⁴, Fröhlich Holger⁵, Therese Gjesten Martha⁶, Marquardt Gaby⁷, Müllenborn Matthias⁸, Nikolopoulos Spiros⁹, Schirmer Timo¹⁰, Aarsland Dag¹¹
¹IOPPN, King's College London - London (United Kingdom), ²GN Hearing - Copenhagen (Denmark), ³University of Exeter - London (United Kingdom), ⁴Alzheimer's Europe - Luxembourg (Luxembourg), ⁵Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Bonn (Germany), ⁶Stavanger Hospital - Stavanger (Norway), ⁷Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Erlangen (Germany), ⁸Novo Nordisk - Copenhagen (Denmark), ⁹CERTH - Thessaloniki (Greece), ¹⁰GE Healthcare - Greater Munich (Germany), ¹¹IOPPN - London (United Kingdom)
- P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials**
Viswanath Devanarayan¹, Pallavi Sachdev¹, Arnaud Charil¹, Yuanqing Ye¹, Todd Nelson¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadha¹, Michael Irizarry¹
¹Eisai Inc. - Nutley (United States)
- P008 Utilizing a Patient Burden Scoring Tool to Improve the Patient and Caregiver Experience in Clinical Research in Patients with Alzheimer's Disease and Other Forms of Dementia**
Jessica Sheldon¹, Ana Manera², Andreas Lysandropoulos³
¹Parexel - Boston (United States), ²Parexel - Quebec (Canada), ³Parexel - Brussels (Belgium)
- P009 Assessing the feasibility of implementing blood-based biomarkers as confirmatory diagnostic tools for early Alzheimer's disease in real-world clinical practice: a prospective, multi-clinic implementation science and observational study**
Leah Zullig¹, Jo Vandercappellen², Marwan N Sabbagh³, Soeren Mattke⁴, Harald Hampel², Richard Batrla², Daryl Jones²
¹Department of Population Health Sciences, Duke University School of Medicine - Durham, (United States), ²Eisai Inc., Nutley - New Jersey (United States), ³Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center - Phoenix (United States), ⁴Center for Economic and Social Research, University of Southern California - Los Angeles (United States)
- P010 A new precision-prevention approach combining lifestyle changes and metformin repurposing for the prevention of cognitive decline: MET-FINGER trial protocol and update**
Alina Solomon^{1,2,3}, Mariagnese Barbera^{1,2}, Dinithi Perera^{2,4}, Arzish Haqqee², Jenni Lehtisalo^{1,5}, Malin Aspö^{3,6}, Mary Cross², Celeste De Jager², Emanuela Falaschetti², Naomi Friel², Jack Message², Geraint Price², Charlotta Thunborg^{3,6}, Francesca Mangialasche^{3,4}, Lefkos Middleton^{2,7}, Tiia Ngandu^{5,3}, Miia Kivipelto^{3,6,2,4}
¹University of Eastern Finland - Kuopio (Finland), ²Imperial College London - London (United Kingdom), ³Karolinska Institutet - Stockholm (Sweden), ⁴FINGERS Brain Health Institute - Stockholm (Sweden), ⁵The Finnish Institute for Health and Welfare - Helsinki (Finland), ⁶Karolinska University Hospital - Stockholm (Sweden), ⁷Imperial College Healthcare NHS Trust Hospitals - London (United Kingdom)
- P011 Evidence-Based Reporting of Ethnicity in Clinical Trials**
Zunera Khan¹, Daniel Kramarczyk², Miguel Vasconcelos Da Silva², Kamara Mcleish Israel², Dag Aarsland², Clive Ballard³
¹Psychological Medicine - London (United Kingdom), ²Psychological Medicine - 6 De Crespigny Park, London (United Kingdom), ³University of Exeter - Exeter (United Kingdom)

POSTER PRESENTATIONS

- P012 Diversity in a Registrational Trial for AriBio's AR1001 for Treatment of Early Alzheimer's Disease**
Sharon Sha¹, Yaneicy Gonzalez², Marshall Nash³, James Rock⁴, Fred Kim⁴, Adam Schindler⁴, Tianyang Xi⁴, Jai Jun Choung⁴
¹Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), ²Verus Clinical Research Corp - Miami (United States), ³Alcanza Research Site Network - NeuroStudies - Decatur (United States), ⁴AriBio Co., Ltd. - San Diego (United States)
- P013 Estimating the benefits of pre-screening Alzheimer's trials using blood-based biomarkers and digital cognitive assessments**
Nicklas Linz¹, Raphael Ullmann², Johannes Tröger¹, Alexandra König¹, Ruth Croney³, Tobias Bittner⁴, Thanneer Perumal²
¹ki:elements GmbH - Saarbrücken (Germany), ²Roche Pharma Research and Early Development, Roche Innovation Center Basel - Basel (Switzerland), ³Roche Products Ltd - welwyn Garden City (United Kingdom), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- P014 Comparison of the screen failure rate in Alzheimer's clinical trials of immunotherapies between the clinical research center of Toulouse and the overall rate over the past 5 years.**
Delphine Pennetier¹, Davide Angioni¹, Isabelle Carrie¹, Nathalie Sastre¹, Julien Delrieu¹, Bruno Vellas¹, Pierre Jean Ousset¹
¹Centre de Recherche Clinique du Gerontopole, IHU Healthage - Toulouse (France)
- P015 Comparing In-study Performance of Experienced and Naïve Raters in Early AD Clinical Trials**
Xingmei Wang¹, Alan Kott², David Miller¹
¹Signant Health - Blue Bell, Pa (United States), ²Signant Health - Prague (Czech Republic)
- P016 Automatic Screening for CDR Stages in the Swedish H70 Birth Cohort Using a Digital Speech Biomarker for Cognition SB-C**
Elisa Mallick¹, Fredrik Öhman², Nicklas Linz¹, Alexandra König¹, Michael Schöll², Silke Kern², Johannes Tröger¹, Ingmar Skoog²
¹ki elements GmbH - Saarbrücken (Germany), ²Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden)
- P017 Enhancing Clinical Trial Efficiency in Alzheimer's Disease: An Application of Prognostic Scoring Adjustments to Address Heterogeneity**
Harry Parr¹, Jeffrey Lin², Doug Thompson¹, Dave Inman¹, Aris Perperoglou¹
¹GSK - London (United Kingdom), ²GSK - Philadelphia (United States)
- P018 Impact of Travel Distance and Participant Age on Potential Alzheimer's Disease Trial Participant Attendance and Clinical Trial Eligibility**
Sarah Starling¹, Ashli Pratt², Adam Rosen², Sophie Barr², Bryanna Billy², Gaby Munoz², Mark Rapp²
¹Adams Clinical - Watertown (United States), ²Berman Clinical - New York (United States)
- P019 Integrating a Speech-based Prescreening Tool in Central Recruitment Strategies for Alzheimer's Disease Clinical Trials: A Pilot Study**
Caroline Skirrow¹, Allan Block², Nicole Hank², Jack Weston¹, Emil Fristed¹, James Rock³
¹Novoic Ltd - London (United Kingdom), ²Perseverance Research Center - Scottsdale, Az (United States), ³AriBio - San Diego, Ca (United States)
- P020 Impact of screening call duration on initial evaluation attendance rate for Alzheimer's Disease drug trials**
Yu-Jay Huoh¹, Brenda Martinez¹, Sydney Hopkins¹, Elizabeth Sosa¹, K. Jade Sanchez¹, Jennifer Mitolo¹, Tara Parnithikul¹, Elly Lee¹, Ralph Lee¹
¹Irvine Clinical Research - Irvine (United States)

THEME 02: Clinical Trials: Results

- P021 Phase 1 clinical trial of Leucettinib-21, a DYRK1A kinase inhibitor aiming at the correction of cognitive disorders in Alzheimer's disease and Down syndrome**
Laurent Meijer¹, Emilie Chrétien¹, Emmanuel Deau¹, Gaëlle Hogrel¹, Mattias F. Lindberg¹
¹Perha Pharmaceuticals - Roscoff (France)
- P022 Combining a multimodal lifestyle intervention with epigallocatechin gallate (EGCG) in APOE-B4 carriers with Subjective Cognitive Decline: the Pensa Study randomized, double-blinded clinical trial**
Natalia Soldevila-Domenech¹, Laura Forcano¹, Anna Boronat¹, Albert Puig-Pijoan¹, Thais Lorenzo¹, Aida Cuenca-Royo¹, Gonzalo Sánchez-Benavides², Iris Piera¹, Carolina Minguillón², Nieves Pizarro¹, Ana Aldea-Perona¹, Juan Domingo Gispert², Oriol Grau-Rivera², Jose Luis Molinuevo², Rafael De La Torre²
¹Hospital del Mar Research Institute, Barcelona, Spain - Barcelona (Spain), ²BarcelonaBeta Brain Research Center, Barcelona, Spain - Barcelona (Spain)
- P023 Effect of treatment with E6b761 on blood markers of inflammation and oxidative stress in a cohort of patients with Mild Cognitive Impairment (ACE-2020-E6b761)**
Xavier Morató¹, Maria Eugenia Sáez², Maria Capdevila-Bayo³, Amanda Cano¹, Juan Pablo Tartari¹, Laia Montoliu-Gaya⁴, Hanna Huber⁴, Asuncion Lafuente¹, Marta Marquí¹, Marta Ibarria¹, Miren Gurruchaga¹, Yahveth Cantero-Fortiz¹, Henrik Zetterberg⁴, Agustin Ruiz¹, Merce Boada¹
¹Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya - Barcelona (Spain), ²Andalusian Bioinformatics Research Centre, CAEBI - Sevilla (Spain), ³Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, Universitat de Barcelona - Barcelona (Spain), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Shagrens Academy at the University of Gothenburg - Mölndal (Sweden)
- P024 Comprehensive analysis of phase 2 trial results and post-hoc findings of ABvac40, an anti-Aβ40 vaccine**
María Pascual-Lucas¹, Ana María Lacosta¹, María Montañés¹, Jesús Canudas¹, Jorge Loscos¹, José Antonio Allué¹, Leticia Sarasa¹, Noelia Fandos¹, Judith Romero¹, Manuel Sarasa¹, Gerard Piñol-Ripoll², Jose Terencio^{3,1}, Merce Boada^{4,5}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Cognitive Disorders Unit, Cognition and Behaviour Study Group. Hospital Universitari Santa Maria - Lleida (Spain), ³Grifols - Barcelona (Spain), ⁴Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain), ⁵Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain)

- P025 SPECTRISTM Treatment Reduced Alzheimer's Disease Dependence Score in OVERTURE I/II Phase 2 Study**
Ralph Kern¹, Marwan Sabbagh², Mihaly Hajos¹, Brent Vaughan¹, Christian Howell¹, Celine Houser¹, Michael Hull¹, Lily Lee¹
¹Cognito Therapeutics - Cambridge (United States), ²Barrow Neurological Institute - Phoenix (United States)
- P026 SPECTRISTM OVERTURE I responder analysis demonstrates consistent preservation of function and brain structure.**
Ralph Kern¹, Mihaly Hajos¹, Brent Vaughan¹, Celine Houser¹, Alex Konisky¹, Lily Lee¹, Joshua Christensen², Benjamin Haaland², Suzanne Hendrix²
¹Cognito Therapeutics - Cambridge (United States), ²Cognito Therapeutics - Salt Lake City (United States)
- P027 A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease**
Alireza Faridar¹, Nazaret Gamez¹, Aaron Thome¹, Weihua Zhao¹, David Beers¹, Jason Thonhoff¹, Mohammad Nakawah¹, Gustavo Roman¹, Juan Toledo¹, Charles Davis², Maria Pascual¹, Michael Grundman³, Joseph Masdeu¹, Stanley Appel¹
¹Houston Methodist Hospital - Houston (United States), ²CSD Biostatistics - Csd Bioscience (United States), ³Global R&D Partners - Global R&D Partners (United States)
- P028 Long-Term Effects of Fortasyn Connect (Souvenaid) on Brain Atrophy Measures in MCIAD: Results from the Double-Blind Randomised LipiDiDiet Trial**
Tobias Hartmann^{1,2}, Jussi Tohka³, Yawu Liu³, Pieter Jelle Visser^{4,5}, Kaj Blennow^{6,7}, Hilka Soininen^{8,9}, Miia Kivipelto^{8,10,11,12}, Alina Solomon^{8,10,11,12}
¹Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University - Homburg (Germany), ²Department of Experimental Neurology, Saarland University - Homburg (Germany), ³A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio (Finland), ⁴Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), ⁵Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), ⁶Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), ⁷Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁸Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), ⁹Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland), ¹⁰Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Huddinge (Sweden), ¹¹Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), ¹²Ageing and Epidemiology Research Unit, School of Public Health, Imperial College - London (United Kingdom)
- P029 Orally available PRI-002 for the treatment of Alzheimer's disease: Phase 1a data and design of the phase 2a study**
Oliver Peters¹, Janine Kutzsche², Nicoleta Carmen Cosma¹, Gunther Kauselmann³, Gerhard Tischler⁴, Dagmar Jürgens³, Dieter Willbold⁵
¹Charité - Berlin (Germany), ²FZ Jülich - Jülich (Germany), ³Priavoid - Düsseldorf (Germany), ⁴Prinovation - Leipzig (Germany), ⁵Priavoid - Jülich (Germany)
- P030 Screening outcomes and baseline disease characteristics in the Rewind-LB phase 2b clinical trial of neflamapimod in patients with early dementia with Lewy bodies (DLB)**
Stephen Gomperts¹, John-Paul Taylor², Kelly Blackburn³, Amanda Gardner³, Conway Jennifer³, John Alam³, James Galvin⁴
¹Massachusetts General Hospital - Charlestown (United States), ²Newcastle University - Newcastle Upon Tyne (United Kingdom), ³CervoMed - Boston (United States), ⁴Miller School of Medicine - Miami (United States)
- P031 Pre-specified SIGMAR1 Gene Variant Analysis in Phase IIb/III Trial Supports Precision Medicine Mechanism of Action (MoA) with Improved Treatment Effect of Blarcamesine in Early Alzheimer Disease**
Marwan N. Sabbagh¹, Juan Carlos Lopez-Talavera², Kun Jin², William Robert Chezem², Christopher U. Missling²
¹Barrow Neurological Institute - Phoenix (United States), ²Anavex Life Sciences - New York (United States)
- P032 A Phase 1 Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses of CS6253 in Healthy Volunteers**
Jan O. Johansson¹, Bengt Winblad², Daniel M. Michaelson³, Henrik Zetterberg⁴, Henrik Zetterberg⁵, Jeffrey L. Cumming⁶, Hussein N. Yassine⁷
¹Artery Therapeutics, Inc. - San Ramon (United States), ²Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), ³Tel Aviv University - Tel Aviv (Israel), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ⁵Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, Dementia Research Institute - London (United Kingdom), ⁶Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas - Las Vegas (United States), ⁷University of Southern California - Los Angeles (United States)
- P033 Harnessing Peripheral Immunity in Early Alzheimer's Disease: Safety and Tolerability of IBC-Ab002 in a Phase 1b Clinical Trial**
Tommaso Croese¹, Kuti Baruch¹, Eti Yoles¹, Alex Kertser¹, Eliezer Schochat², Michal Schwartz³, Keswani Sanjay¹
¹ImmunoBrain Checkpoint Inc. - New York, ²Schochat Pharma Services - Basel, ³Weizmann Institute of Science - Rehovot (Israel)
- P034 Hyperbaric oxygen therapy for cognition in older adults with type 2 diabetes**
Michal Schnaider Beeri¹, Ori Benari^{2,3}, Shai Efrati², Mary Sano⁴, Barbara B Bendlin⁵, Abigail Livny², Maayan Harel³, Ganit Almog³, Yuxia Ouyang⁴, Yael Mardor³, Amir Hadanny⁶, Ramit Ravona-Springer^{3,2}
¹Herbert and Jacqueline Krieger Klein Alzheimer's Research Center, Robert Wood Johnson Medical School, Rutgers University - New Brunswick (United States), ²Faculty of Medicine, Tel Aviv University - Tel Aviv (Israel), ³Sheba Medical Center - Ramat Gan (Israel), ⁴Department of Psychiatry, Icahn School of Medicine at Mount Sinai - New York (United States), ⁵Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison - Wisconsin (United States), ⁶Shamir Medical Center - Rishon LeZion (Israel)
- P035 Health Economic Impact of Disease Modifying Therapies such as Monoclonal Antibodies**
Samuel Dickson¹, Craig Mallinckrodt¹, Suzanne Hendrix¹
¹Pentara Corporation - Salt Lake City (United States)
- P036 Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep**
Sung Yong Park¹, Won-Myong Bahk², Bo-Hyun Yoon³, Kwanghun Lee⁴, Sang-Yeol Lee⁵, Hyung Mo Sung⁶, Min-Kyu Song⁷
¹Keyo Hospital - Uiwang (Korea, Republic of), ²Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul - Seoul (Korea, Republic of), ³Naju National Hospital - Naju-Si (Korea, Republic of), ⁴College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ⁵Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁶Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁷St. Mary's Gong-Gam Mental Health Clinic - Sihung (Korea, Republic of)

POSTER PRESENTATIONS

- P037** **Analysis of the cardiovascular safety of choline alfoscerate treatment in the ASCOMALVA trial**
Enea Traini¹, Anna Carotenuto¹, Angiola Fasanaro², Francesco Amenta¹
¹University of Camerino - Camerino (Italy), ²Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)
- P038** **Exploring the effect of baseline characteristics on the efficacy of multidomain dementia prevention in late-life: a pooled analysis of individual participant data from the MAPT and preDIVA trials**
Nicola Coley^{1,2,3}, Marie Hoevenaer-Blom^{4,5}, Jason Shourick^{1,2,3}, Eric Moll Van Charante^{4,5}, Jan-Willem Van Dalen^{6,7}, Willem Van Gool⁵, Edo Richard⁵, Sandrine Andrieu^{1,2,3}
¹Aging Research Team, Centre for Epidemiology and Research in Population health (CERPOP), INSERM-University of Toulouse UPS - Toulouse (France), ²Department of Epidemiology and Public Health, Toulouse University Hospital - Toulouse (France), ³IHU HealthAge - Toulouse (France), ⁴Department of General Practice, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), ⁵Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), ⁶Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center - Nijmegen (Netherlands), ⁷Department of Neurology, Amsterdam University Medical Center, Location AMC - Amsterdam (Netherlands)
- P039** **Online advertising resulted in more educated participants and non inferior screen fail rates when compared to offline methods in an Alzheimer's disease clinical trial**
 Yu-Jay Huoh¹, Ralph Lee¹, Colin Sholes¹, Brenda Martinez¹, Sydney Hopkins¹, Jennifer Mitolo¹, Tara Parnitvithikul¹, Edward Zamrini¹, Elly Lee¹
¹Irvine Clinical Research - Irvine (United States)
- P040** **Potential Efficacy of Oral Nicotinamide Riboside (NR) Supplementation in Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment**
Chao-Yi Wu¹, Ashley Kupferschmid¹, Alison Mcmanus¹, Pia Kivisakk¹, Jake Galler¹, Nadine Schwab¹, Libby Desruisseaux¹, Victoria Williams¹, Jessica Gerber¹, Misha Riley¹, Cathrine Young¹, Hiroko Dodge¹, Rudolph Tanzi¹, Clifford Singer², Steven Arnold¹
¹Massachusetts General Hospital/ Harvard Medical School - Boston (United States), ²Northern Light Health - Bangor (United States)



THEME 11: New therapies and clinical trials

- P041** **Digital Interventions in Neuro-Rehabilitation: Gotcha! app-based therapy for proper name anomia in people with dementia**
Aygun Badalova¹
¹Institute of Neurology, University College London - London (United Kingdom)
- P042** **Specialized infrastructure in a tertiary hospital to administer disease modifying treatments in Alzheimer's disease**
Talya Nathan¹, Elissa Ash^{1,2,3}, Shir Dror¹, Noa Trabulus¹, Aya Bar-David¹, Mori Hay Levy¹, Galia Wolpe¹, Tamara Shiner^{1,2,3}, Noa Bregman^{1,2,3}
¹Cognitive Neurology Unit, Tel Aviv Sourasky Medical Center - Tel Aviv (Israel), ²Department of Neurology and Neurosurgery, Sackler School of Medicine, Tel Aviv University - Tel Aviv (Israel), ³Sagol School of Neuroscience, Tel Aviv University - Tel Aviv (Israel)
- P043** **Cognitive Vergence predicts AD, correlates with CSF biomarkers and improves after digital treatment.**
Hans Supèr¹
¹University of Barcelona - Barcelona (Spain)
- P044** **Increasing Representation and Diversity in Clinical Trials of Alzheimer's Disease: Recruitment of Ethnically Diverse Participants with Alzheimer's Disease in the Phase 1 ASCENT Clinical Trials of PRX012**
Chad Swanson¹, Ferenc Martényi¹, Ryan E. Tooker¹, Donna Masterman¹, Courtney Fitzgerald¹, Ann Johnson¹, Lingnan Li¹, Mary E. Quiceno¹, Gene G. Kinney¹, Hideki Garren¹
¹Prothena Biosciences Inc - Brisbane (United States)
- P045** **Advances in Clinical Trials for Alzheimer's Disease in Down Syndrome**
Michael Rafii¹, Juan Fortea², Beau Ances³
¹University of Southern California - San Diego (United States), ²Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ³Washington University - Saint Louis (United States)
- P046** **Clinical experience with amyloid-lowering treatments in an academic dementia specialty practice**
Madeline Paczynski¹, Suzanne Schindler^{1,2}, Erik Musiek^{1,2}, David Holtzman^{1,2}, Tammie Benzinger^{1,2}, Alan Dow³, Sheyda Namazie-Kummer³, Zachary Posey^{1,2}, Dawn Ellington^{1,2}, John Morris^{1,2}, Barbara Snider^{1,2}
¹Washington University School of Medicine - Saint Louis (United States), ²Knight Alzheimer Disease Research Center - Saint Louis (United States), ³Barnes Jewish Corporation - Saint Louis (United States)
- P047** **A randomized, double-blind trial of the effects of a live biotherapeutic product in preclinical Alzheimer's disease**
Kun Ho Lee¹, Kyu Yeong Choi², Sarang Kang¹, Junho H Lee³, Won-Seok Choi³, Jung Hee Lee²
¹Gwangju Alzheimer's & Related Dementia Cohort Research Center, Chosun University - Gwangju (Korea, Republic of), ²Kolab Inc. - Gwangju (Korea, Republic of), ³Chonnam National University - Gwangju (Korea, Republic of)
- P048** **Investigating the Effect of Glycerol Phenylbutyrate on Neurofilament Light Chain Levels in Patients with Corticobasal Syndrome: The PROFIL Study**
Johannes Levin¹, Carla Palleis¹, Lennart Schlaphoff¹, Endy Weidinger¹, Sylvia Maass², Günter Höglinger¹, Mikael Simons²
¹Department of Neurology, LMU Munich - Munich (Germany), ²German Center for Neurodegenerative Diseases - Munich (Germany)

- P049 Self-reported sleep quality and amyloid burden in cognitively unimpaired adults from the AMYPAD study.**
Núria Tort-Colet^{1,2}, Laura Stankeviciute¹, Craig Ritchie³, Mercè Boada^{4,5}, Wiesje Van Der Flier⁶, Bernard J Hanseeuw⁷, Pablo Martinez-Lage⁸, Pieter Jelle Visser⁹, Michael Schöll¹⁰, Giovanni B Frisoni¹¹, Chris Buckley¹², Frank Jessen¹³, Lyduine E. Collij^{9,14}, Frederik Barkhof^{9,14,15}, Oriol Grau-Rivera^{1,2,16,17}
¹BBRC, Pasqual Maragall Foundation - Barcelona (Spain), ²Hospital del Mar Research Institute - Barcelona (Spain), ³Centre for Clinical Brain Sciences, University of Edinburgh - Edinburgh (United Kingdom), ⁴ACE Alzheimer Center Barcelona - Barcelona (Spain), ⁵CIBERNED, Instituto de Salud Carlos III - Madrid (Spain), ⁶Amsterdam UMC Location VUmc - Amsterdam (Netherlands), ⁷IONS, Université Catholique de Louvain - Brussels (Belgium), ⁸Fundacion CITA Alzheimer - San Sebastian (Spain), ⁹Amsterdam University Medical Center, location VUmc - Amsterdam (Netherlands), ¹⁰University of Gothenburg - Gothenburg (Sweden), ¹¹LANVIE, Université de Genève - Geneva (Switzerland), ¹²GE Healthcare - Amersham (United Kingdom), ¹³University Hospital of Cologne - Cologne (Germany), ¹⁴Amsterdam Neuroscience, Brain Imaging - Amsterdam (Netherlands), ¹⁵Centre for Medical Image Computing, and Queen Square Institute of Neurology, UCL - London (United Kingdom), ¹⁶Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), ¹⁷Hospital del Mar - Barcelona (Spain)
- P050 Phase 1, First-in-human, Single and Multiple Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG-3927) in Healthy Volunteers: Interim Results**
Raj Rajagovindan¹, Francois Gaudreault¹, Ryan O'mara¹, Jade Donaldson¹, Evan Thackaberry¹, Jessica Stromme¹, David Gray¹, Andreas Meier², Petra Kaufmann¹
¹Vigil Neuroscience, Inc - Watertown (United States), ²Formerly Vigil Neuroscience, Inc - Watertown (United States)
- P051 Interim Safety and Biomarker Data From upliFT-D, a Phase 1b Trial of PBT02 in Frontotemporal Dementia and Mutations in the Granulin Gene (FTD-GRN)**
Juan Chavez¹, Tiffini Voss¹, Paulette Triglia¹, Yan Ni¹, Sue Browne¹, Karen Quadrini¹, Sarang Rastogi¹, Simon Ducharme², David Irwin³, Isabel Santana⁴, Paul E Schulz⁵, Leonel Takada⁶, Maria Tartaglia⁷, Leonardo Cruz De Souza⁸, Mark S Foreman¹
¹Passage Bio - Philadelphia (United States), ²Douglas Mental Health University Institute and Montreal Neurological Institute, McGill University - Montreal (Canada), ³Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ⁴Centro Hospitalar Universitário de Coimbra - Coimbra (Portugal), ⁵McGovern Medical School, UTHealth Houston - Houston (United States), ⁶Perelman School of Medicine at the University of Pennsylvania - Sao Paulo (Brazil), ⁷University Health Network, and Tanz Centre for Research In Neurodegenerative Diseases - Toronto (Canada), ⁸Hospital das Clinicas Universidade Federal de Minas Gerais - Belo Horizonte (Brazil)
- P052 Alzheimer's disease and microbiota: the MICMALZ study**
Germain Busto¹, Lucy Kundura², Sylvaine Artero², Yves Dauvilliers³, Karim Bennys⁴, Sylvie Claeysen², Audrey Gabelle¹
¹Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, INM, Univ Montpellier, Montpellier, France - Montpellier (France), ²IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France - Montpellier (France), ³Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital and INM, Univ Montpellier, Montpellier, France - Montpellier (France), ⁴Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, France - Montpellier (France)
- P053 TREM2 Agonism Stimulates Human Microglia Responses in the Presence of Amyloid Pathology**
Manuela Polydoro¹, Ivana Geric², Jin Zheng³, Tina Sommer Bisgaard³, Leen Wolfs², Anke Misbaer², Arya Nair², Laura Sans³, Maria Dalby³, Joachim Vilstrup³, Peter Flagstad³, Rita Balice-Gordon⁴, Bart De Strooper^{5,6}, Niels Plath³
¹Muna Therapeutics, Copenhagen, Denmark - Boston (United States), ²Muna Therapeutics, Copenhagen, Denmark - Leuven (Belgium), ³Muna Therapeutics, Copenhagen, Denmark - Copenhagen (Denmark), ⁴Muna Therapeutics, Copenhagen, Denmark - Philadelphia (United States), ⁵UK Dementia Research Institute - London (United Kingdom), ⁶KU Leuven - Leuven (Belgium)
- P054 Targeting α -Synuclein Fibril's Disordered Region with Small Molecule Inhibitors: A Therapeutic Strategy for Parkinson's Disease**
Shenqing Zhang¹, Huaijiang Xiang², Dan Li¹, Li Tan², Cong Liu²
¹Shanghai Jiao Tong University - Shanghai (China), ²Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China)
- P055 Different charged biopolymers induce α -synuclein to form fibrils with distinct structures**
Yuxuan Yao¹, Qinyue Zhao¹, Cong Liu², Dan Li³
¹Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University - Shanghai (China), ²Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China), ³Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University - Shanghai (China)
- P056 Development and Efficacy Assessment of a Video-Based Reminiscence Therapy Using Media Archives for Early-Stage Dementia: A Pilot Study**
Geon Ha Kim¹, Bori.r Kim^{1,2}, Sumin Kim¹, Jee Hyang Jeong³
¹Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of), ²Ewha Medical Research Institute, Ewha Womans University - Seoul (Korea, Republic of), ³Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of)
- P057 PreDXClearance, exploring new biomarkers to predict ARIA/CAA and personalize therapy in AD**
Fanni Ujvarosi¹, Line Amundsen¹, Jie Gao¹, Ira Hebold Haraldsen², Fernando Maestú³, Hanna Hanna Renvall⁴, Camillo Marra⁵, Paolo M. Rossini⁶, Erik Christensen¹, Maria J. Lagartos¹
¹Pre Diagnostics - Oslo (Norway), ²Oslo University Hospital - Oslo (Norway), ³Universidad Complutense - Madrid (Spain), ⁴HUS - Helsinki (Finland), ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁶IRCCS San Raffaele - Rome (Italy)
- P058 Evaluation of square-stepping exercise on plasma amyloid-beta levels and cognitive function in older adults: a randomized controlled trial**
Jieun Yoon¹, Tomohiro Okura¹
¹University of Tsukuba - Tsukuba (Japan)

POSTER PRESENTATIONS

- P059** **Evaluation of an Upper Alpha Neurofeedback Intervention on Mild Amnesic Cognitive Impairment: A Randomized, Double-blind, Sham-controlled Research Project (ESPERANZA study)**
Esperanza Jubera Garcia¹
¹Bitbrain - Zaragoza (Spain)
- P060** **Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer's Disease**
 Abigail Silber¹, Amod Athavale¹, Matthew O'hara¹, Donna Masterman², Preeti S. Bajaj²
¹Trinity Life Sciences - Waltham, Ma (United States), ²Prothena Biosciences, Inc - Brisbane, Ca (United States)
- P061** **The NANA study: Auditory simulation during sleep as a symptomatic treatment for mild cognitive impairment**
Javier Minguez¹
¹Bitbrain - Zaragoza (Spain)
-  **P062** **Prospects for the Treatment of Alzheimer's Disease**
Amanda Scarso¹, Gustavo Santos¹, Gabrielle Almeida¹
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)

THEME 14: Beyond Amyloid and Tau

- P063** **Novel blood-based mitochondrial biomarkers for the prognosis of progression from mild cognitive impairment to Alzheimer's Disease Dementia**
 Jose Luis Mosquera¹, Marta Blanch¹, Nuria Rojo², Jaume Campdelacreu², Joan Bello³, Alberto Lleo⁴, Pablo Martínez-Lage⁵, Adrià Tort-Merino⁶, Raquel Sanchez-Valle⁶, Carlos Cruchaga⁷, Christopher Fowler⁸, Simon Laws⁹, Courosh Mehanian¹⁰, Jordi Gascon-Bayarri², Marta Barrachina¹
¹ADmit Therapeutics - Barcelona (Spain), ²Bellvitge University Hospital - IDIBELL - Barcelona (Spain), ³Complex Hospitalari Moisès Broggi. L'Hospitalet/Sant Joan Despí - Barcelona (Spain), ⁴Institut de Recerca Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona - CIBERNED - Barcelona (Spain), ⁵CITA-alzheimer Foundation - San Sebastián (Spain), ⁶Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona - Barcelona (Spain), ⁷Washington University School of Medicine - Saint Louis (United States), ⁸The Florey Institute, The University of Melbourne - Melbourne (Australia), ⁹Collaborative Genomics and Translation Group, Edith Cowan University - Joondalup (Australia), ¹⁰University of Oregon and Global Health Labs - Eugene (United States)
- P064** **Misfolding of alpha-synuclein as a direct biomarker for Parkinson's Disease and Synucleinopathies**
Klaus Gerwert¹
¹Ruhr-University Bochum - Bochum (Germany)
- P065** **Phenome-wide Mendelian randomization analysis reveals shared causal risk factors among Alzheimer's disease, vascular dementia, and stroke**
 Chi-Hun Kim¹, Jong Hun Kim², Hyoung Seop Kim²
¹Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of), ²Ilisan Hospital, National Health Insurance Service - Goyang (Korea, Republic of)
- P066** **The N-glycan structure bisecting N-acetylglucosamine predicts cognitive decline in patients from a memory clinic cohort**
 Robin Zhou¹, Bengt Winblad¹, Lars Tjernberg¹, Sophia Schedin Weiss¹
¹Karolinska Institutet - Solna (Sweden)
- P067** **Peak width of skeletonized mean diffusivity on MRI differentiates cerebral amyloid angiopathy from non-amyloid cerebral small vessel disease in non-demented older adults**
Lene Pålhaugen^{1,2}, Julia K. Gundersen^{1,2}, Sandra Tecelão¹, Jonas Alexander Jarholm^{1,2}, Bjørn-Eivind Kirsebom^{1,2,3,4}, Atle Bjørnerud^{5,6}, Per Selnes^{1,2}, Tormod Fladby^{1,2}
¹Department of Neurology, Akershus University Hospital - Lørenskog (Norway), ²Institute for Clinical Medicine, University of Oslo - Oslo (Norway), ³Department of Neurology, University Hospital of North Norway - Tromsø (Norway), ⁴Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway - Tromsø (Norway), ⁵Department of Physics and Computational Radiology, Oslo University Hospital - Oslo (Norway), ⁶Center for Lifespan Changes in Brain and Cognition, University of Oslo - Oslo (Norway)
- P068** **Association between accelerated epigenetic and inflammatory aging and cognitive function in men and women: a cross-sectional analysis from the INSPIRE-T cohort**
 Samuel Thuriot¹, Jason Shourick¹, Mathilde Strumia¹, Vanina Bongard¹, David Furman², Jean-Marc Lemaître³, Sophie Guyonnet¹, Heike Bischoff-Ferrari¹, Bruno Vellas¹, Sandrine Andrieu¹, Laure Rouch¹
¹IHU HealthAge - Toulouse (France), ²Buck Institute for Research on Aging - Novato (United States), ³INSERM 1183 Institute of regenerative medicine and Biotherapies - Montpellier (France)
- P069** **Towards a cortical microstructural signature of neuroinflammation in AD**
Gerard Ridgway¹, Mario Torso¹, Ian Hardingham¹, Steven Chance¹, & For The Alzheimer's Disease Neuroimaging Initiative²
¹Oxford Brain Diagnostics Ltd - Oxford (United Kingdom), ²Alzheimer's Disease Neuroimaging Initiative - San Francisco (United States)
- P070** **Associations of LATE-NC with past medical history and medication use: an exploratory analysis using data from the National Alzheimer's Coordinating Center**
Davis Woodworth¹, Joey Wong¹, Anne-Marie Leiby¹, S. Ahmad Sajjadi¹
¹University of California, Irvine - Irvine (United States)

- P071** Association between the long-term use of high anticholinergic drugs and its burden and the incidence of dementia in stroke.
Ahmed Alharthi^{1,2}, Terry Quinn¹, Donald Lyall¹
¹University of Glasgow - Glasgow (United Kingdom), ²Umm Al-Qura University - Makkah (Saudi Arabia)
- P072** Diagnostic Performance of Plasma Alzheimer's Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration
Hanna Cho¹, Han-Kyeol Kim¹, Jae Hoon Lee², Jeong-Ha Lee¹, Joong-Hyun Chun³, Tim West⁴, Kris Kermess⁴, Philip Verghese⁴, Daniel Connell⁴, Joel Braunstein⁴, Young Hoon Ryu², Chul Hyoung Lyoo¹
¹Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ²Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ³Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ⁴C2N diagnostics - St Louis (United States)
- P073** Sarcopenia is a predictor for Alzheimer's continuum and related clinical outcomes
Sung Hoon Kang¹, Yu Jeong Park¹, Chi Kyung Kim¹
¹Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of)
- P074** Neuroinflammatory CSF markers associated with cerebrovascular lesions in Alzheimer's disease
Linbin Dai¹, Qiong Wang¹, Feng Gao¹, Yong Shen¹
¹University of Science and Technology of China - Hefei (China)
- P075** Discovery of a Novel C3-Targeting and CNS Active siRNA as a Potential Therapeutic for Alzheimer's Disease
Tara Barbour¹, Fay Touti¹, Yan Li¹, Anshu Jain¹, Elisabeth Lonie¹, Salome Funes¹, Andrew Carvalho¹, Maggie Mohr², Justin Guo³, Matthew Poulin⁴, Anke Geick⁵, Soham Mandal⁵, Zhouning Zhang¹, Kate Lane¹, Lukas Scheibler¹, David Eyerman¹
¹Apellis Pharmaceuticals - Waltham (United States), ²Northern Biomedical Research - Norton Shores (United States), ³Synoligo Biotechnologies - Morrisville (United States), ⁴EpigenDx - Hopkinton (United States), ⁵Axolabs GmbH - Kulmbach (Germany)

THEME 15: Clinical Trials Early Career Investigator Showcase

- P076** Neuropathology after treatment with aducanumab and amyloid related imaging abnormalities
Baayla D.C. Boon¹, Yoav Piura¹, Jessica L Chalk¹, Kelly M Hinkle¹, Christina M Moloney¹, Sarah J Lincoln¹, Matthew H Rutledge¹, Derek R Johnson², Dennis W Dickson¹, Aivi T Nguyen², R. Ross Reichard², Jonathan Graff-Radford², Melissa E Murray¹, David S Knopman², Neill R Graff-Radford¹
¹Mayo Clinic - Jacksonville (United States), ²Mayo Clinic - Rochester (United States)
- P077** High prevalence of brain amyloidopathy among frail older adults: are they eligible for anti-amyloid treatments? Should they be treated? Evidence from the real-life Cogfrail cohort
Davide Angioni¹, Sandrine Sourdet¹, Julien Delrieu¹, Gaëlle Soriano¹, Alberta Peluso¹, Gabor Abellan¹, Pierre-Jean Ousset¹, Bruno Vellas¹
¹Institut Hospitalo Universitaire HealthAge, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital - Toulouse (France)
- P078** Drug-induced cutaneous vasculitis from Alzheimer's disease trial medications: A case series from e2814 and literature review
David Jakabek¹, Janine Cesar-Howells², Jennifer Laude², Alexandra Pone Lameirinhas², Catherine Mummery¹
¹Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London - London (United Kingdom), ²Leonard Wolfson Experimental Neurology Centre, National Hospital for Neurology and Neurosurgery, University College London Hospital - London (United Kingdom)

POSTER SESSION 2: From Thursday, October 31 - 7:15 a.m. to Thursday, October 31 - 5:00 p.m.

THEME 3: Clinical Trials: imaging



- P079** **Effects of multimodal art-based intervention on cognitive functions and amplitude of low-frequency fluctuation of resting-state functional MRI in older adults with cognitive impairments: A randomised controlled trial**
Yuanjiao Yan¹, Yanhong Shi², Chenshan Huang², Rong Lin², Hong Li²
¹Fujian Provincial Hospital - Fuzhou (China), ²Fujian Medical University - Fuzhou (China)
- P080** **Longitudinal Regional Volume Changes in the Cerebellum Across the Alzheimer's Disease Spectrum**
Um Yoo Hyun¹, Kim Suhung¹, Wang Sheng-Min¹, Kang Dong Woo¹, Kim Sunghwan¹, Lim Hyun Kook¹
¹College of Medicine, Catholic University of Korea - Seoul (Korea, Republic of)
- P081** **Art-based intervention alters brain functional network connectivity in older adults with mild cognitive impairment--a graph theory analysis**
Rong Lin¹, Hong Li¹
¹Fujian Medical University - Fuzhou (China)
- P082** **Data-driven subtypes of white matter lesions are differentially associated with vascular and Alzheimer's pathology**
Lyduine E. Collin^{1,2}, Sophie E. Mastenbroek^{3,2}, Katja Steijn^{3,2}, Carole Sudre⁴, Danielle Van Westen³, Olof Strandberg³, Niklas Mattsson-Carlsson³, Sebastian Palmqvist³, Erik Stomrud³, Jacob E Vogel³, Rik Ossenkoppele^{2,3}, Oskar Hansson¹
¹Lund University - Lund (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³Lund University - Lund (Sweden), ⁴King's College London - London (United Kingdom)
- P083** **Neuroimaging data harmonization in multisite studies of Alzheimer's Disease and potential implications on effect sizes in clinical trials.**
Dana Tudorascu¹, Alex Delbene¹, Alexandra Gogola¹, Weiquan Luo¹, Charles Laymon¹, Changlee Chen¹, Mahbaneh Torbati¹, Val Lowe², David Soleimani-Meigooni³, Belen Pascual⁴, Huamee Oh⁵, Brian Gordon⁶, Pedro Rosa-Neto⁷, Tharick Pascoal¹, Suzanne Baker⁸, Davneet Minhas¹
¹University of Pittsburgh - Pittsburgh (United States), ²Mayo Clinic - Rochester (United States), ³University of California at San Francisco - San Francisco (United States), ⁴Houston Methodist - Houston (United States), ⁵Brown University - Providence (United States), ⁶Washington University of St. Louis - St. Louis (United States), ⁷McGill University - Montreal (Canada), ⁸Lawrence Berkeley National Laboratory - Berkeley (United States)
- P084** **Novel regional flortaucipir visual read approaches to stratify subjects by tau spread: Evaluation in TRAILBLAZER-ALZ 2 phase 3 study of donanemab**
Ian Kennedy¹, Min Jung Kim¹, Anupa K Arora¹, Ming Lu¹, Ilke Tunali¹, Leonardo Iaccarino¹, John R Sims¹, Emily C Collins¹, Mark A Mintun¹, Sergey Shcherbinin¹
¹Eli Lilly and Company - Indianapolis (United States)
- P085** **Multicenter Reader Study Assessing Diagnostic Accuracy of Amyloid- β Detection Comparing Real versus AI-based Amyloid- β PET Generated from Brain MRI**
Gregory Mathoux¹, Eliliane Pirazzo Andrade Teixeira¹, Philippe Blanc², Nadya Pyatigorskaya³, Debora-Elisa Peretti⁴, Despoina Ioannidou⁵, Audrey Duran⁵, Gizem Temiz⁵, Shibeshi Belachew⁵, Nikos Paragios⁵, Jacques Touchon⁶, Bruno Vellas⁷, Audrey Gabelle⁶, Pierre Payoux⁸, Giovanni Frisoni⁹, Valentina Garibotto¹⁰
¹Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital - Geneva (Switzerland), ²Nuclear Medicine Department, Centre Hospitalier d'Albi - Albi (France), ³Neuroradiology Department, University Hospitals Pitié Salpêtrière - Paris (France), ⁴Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Faculty of Medicine, Geneva University Neurocenter, University of Geneva - Geneva (Switzerland), ⁵Therapancea - Paris (France), ⁶Faculty of Medicine, University of Montpellier - Montpellier (France), ⁷Gérontopôle, Centre Hospitalier Universitaire de Toulouse - Toulouse (France), ⁸Department of Nuclear Medicine, CHU Toulouse Purpan - Toulouse (France), ⁹Department of Rehabilitation and Geriatrics, Memory Clinic, Geneva University Hospitals - Geneva (Switzerland), ¹⁰Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, University of Geneva - Geneva (Switzerland)
- P086** **Robustness of visual and quantitative assessment of [18F]PI-2620 PET scans evaluated with different mass doses**
Núria Roé-Vellvé¹, Henryk Barthel², Lorelei Howard¹, Norman Koglin¹, Andre Mueller¹, Audrey Perrotin¹, Aleksandar Jovalekic¹, Franziska Ruth Zientek², Michael Rullmann², Marianne Patt², Andreas Schildan², Tobias Jeschke², Olena Mishchenko², Mathias Berndt², Caroline Papin¹, Johnny Castillo-Meleán¹, Andrew Stephens¹, Osama Sabri², Santiago Bullich¹
¹Life Molecular Imaging GmbH - Berlin (Germany), ²Nuclear Medicine Department, University of Leipzig Medical Center - Leipzig (Germany)
- P087** **Evaluation of a sensitive visual read algorithm for assessing tau PET images**
Ruben Smith¹, Valentina Garibotto², Douglas Hägerström³, Jonas Jögi⁴, Tomas Ohlsson⁵, Olof Strandberg¹, Matteo Tonietto⁶, Shorena Janelidze¹, Sebastian Palmqvist¹, Erik Stomrud¹, Gregory Klein⁶, Oskar Hansson¹
¹Lund University, Clinical Memory Research Unit - Malmö (Sweden), ²Division of Nuclear Medicine and Molecular Imaging, Diagnostic department, University Hospitals of Geneva - Geneva (Switzerland), ³Skåne University Hospital, Department of Clinical Neurophysiology - Lund (Sweden), ⁴Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine - Lund (Sweden), ⁵Skåne University Hospital, Department of Radiation Physics - Lund (Sweden), ⁶Hoffman La Roche Ltd. - Basel (Switzerland)
- P088** **Regional Cerebral Hypometabolism and Pathological Heterogeneity in Sporadic Early Onset Alzheimer's Disease using Multi-probes PET/CT**
Zhu Zehua¹, Shi Jiong², Wang Shicun³, Lv Xinyi², Shen Yong²
¹Department of Nuclear Medicine, The First Affiliated Hospital of USTC - Hefei (China) - Hefei (China), ²Department of Neurology, The First Affiliated Hospital of USTC - Hefei (China), ³Department of Nuclear Medicine, The First Affiliated Hospital of USTC - Hefei (China)

- P089 First-in-human PET imaging study of intranasal insulin using the Aptar Cartridge Pump System**
Kiran K Solingapuram Sai¹, Jennifer M Erichsen¹, Krishna Gollapelli¹, Ivan Krizan¹, Mack Miller¹, Charles Cazzola², Reenal Gandhi², Julie Suman², Suzanne Craft¹
¹Wake Forest School of Medicine - Winston Salem (United States), ²Aptar Pharma - Congers (United States)
- P090 FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease**
Youngsoon Yang¹
¹Soonchunhyang University College of Medicine - Cheonan (Korea, Republic of)
- P091 Independent Effects of White Matter Hyperintensities on Frailty for Patients with Alzheimer's Dementia**
Won-Myong Bahk¹, Bo-Hyun Yoon², Kwanghun Lee³, Hyung Mo Sung⁴, Sung-Yong Park⁵, Min-Kyu Song⁶, Moon-Doo Kim⁷, Hyun-Ju Yang⁷, Sang-Yeol Lee⁸
¹Professor, Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Psychiatrist, Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ³Professor, Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ⁴Professor, Department of Psychiatry, Soonchunhyang University Gumi Hospital, - Gumi (Korea, Republic of), ⁵Psychiatrist, Department of Psychiatry, Jeyo Hospital - Uiwang (Korea, Republic of), ⁶Psychiatrist, St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of), ⁷Professor, Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of), ⁸Professor, Department of Psychiatry, Wokwang University School of Medicine - Iksan (Korea, Republic of)
- P092 Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease**
Won-Myong Bahk¹, Bo-Hyun Yoon², Young-Joon Kwon³, Kwanghun Lee⁴, Sang-Yeol Lee⁵, Hyung Mo Sung⁶, Sung-Yong Park⁷, Min-Kyu Song⁸, Sheng-Min Wang¹, Hyun Kook Lim¹
¹Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ³Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of), ⁴Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), ⁵Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁶Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁷Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁸St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)
- P093 Sex-Related Disparities in the Resting State Functional Connectivity of the Locus Coeruleus and Salience Network in Preclinical Alzheimer's Disease**
Kwanghun Lee¹, Hyun Kook Lim², Sheng-Min Wang², Won-Myong Bahk², Bo-Hyun Yoon³, Sang-Yeol Lee⁴, Hyung Mo Sung⁵, Sung-Yong Park⁶, Min-Kyu Song⁷
¹Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ²Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ⁴Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁵Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁶Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁷St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)
- P094 Sex-specific effects of APOE ε4 genotype on longitudinal hippocampal atrophy in mild cognitive impairment due to AD over a 2-year period**
Hyunji Lee¹
¹Pusan National University Hospital - Busan (Korea, Republic of)
- P095 Multicenter study of associations between harmonized tau-PET CentAU values and Alzheimer's disease neuropathology at autopsy: preliminary scope and study design**
Leonardo Iaccarino^{1,2}
¹Eli Lilly and Company - Indianapolis (United States), ²Eli Lilly Italia S.p.A. - Sesto Fiorentino (Italy)
- P096 Sex differences in regional brain volume changes associated with verbal memory in patients with subjective cognitive decline**
Hyuk-Je Lee¹, Bora Yoon¹, Seonghee Ho², Yun Jeong Hong³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁷, Seong Hye Choi⁸, Dong Won Yang¹
¹Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Department of Neurology, Hanyang University Hanmaeum Changwon Hospital - Changwon (Korea, Republic of), ³Department of Neurology, College of Medicine, The Catholic University of Korea, Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), ⁴Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine - Seoul (Korea, Republic of), ⁵Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Roa Neurology Clinic - Seongnam (Korea, Republic of), ⁸Department of Neurology, Inha University School of Medicine - Incheon (Korea, Republic of)
- P097 TSPO PET as inflammation biomarker in dementia**
Belen Pascual¹, Quentin Finn¹, Kaitlee Ornelas¹, Alireza Faridar¹, Jon B Toledo¹, Mohammad O. Nakawah¹, Gustavo C Roman¹, Joseph C Masdeu¹
¹Houston Methodist Research Institute - Houston (United States)
- P098 Enhancing the effectiveness of Alzheimer's disease drug development by assessing tau PET as a promising surrogate endpoint within the pre-competitive Critical Path for Alzheimer's Disease (CPAD) consortium**
Yashmin Karten¹, Dries De Witte², Michael Irizarry³, Gregory Klein⁴, Antoine Leuzy^{1,5}, Klaus Romero¹, Eileen Priest¹, Colleen Jacobsen¹, Abad Ariel Alonso^{2,6}, Geert Molenberghs^{2,6}, Diane Stephenson¹
¹Critical Path Institute - Tucson (United States), ²L-Biostat, KU Leuven - Leuven (Belgium), ³Eisai - Nutley (United States), ⁴F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ⁵Enigma Biomedical USA - Knoxville (United States), ⁶l-BioStat, Hasselt University - Hasselt (Belgium)

- P099** **Voxel-based morphometric analysis of selected brain regions in MCI subjects treated with choline alphoscerate**
Enea Traini¹, Anna Carotenuto¹, Mohamed Hossein¹, Vincenzo Andreone², Amenta Francesco¹
¹Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino - Camerino (Italy), ²Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)
- P100** **Association between the new sub-classified white matter hyperintensities volume and cognitive function in elderly**
Yoon Bo-Hyun¹, Bahk Won-Myong², Lee Kwanghun³, Lee Sang-Yeol⁴, Sung Hyung Mo⁵, Song Min-Kyu⁶, Park Sung-Yong⁷, Kim Moon-Doo⁸, Yang Hyun-Ju⁸
¹Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ²Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), ⁴Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁵Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁶St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of), ⁷Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁸Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of)
- P101** **Allopregnanolone Preserves White Matter Structure Independent of APOE genotype in Early Alzheimer's Disease**
Adam Raikes¹, Gerson Hernandez¹, Claudia Lopez¹, Lon Schneider², Roberta Brinton¹
¹Center for Innovation in Brain Science, University of Arizona - Tucson (United States), ²USC School of Medicine - Los Angeles (United States)

THEME 04: Clinical trials: biomarkers including plasma

- P102** **Determination of plasma biomarkers for the early and specific detection of Alzheimer's disease**
Lourdes Álvarez-Sánchez¹, Carmen Peña-Bautista¹, Laura Ferré-González¹, Laura Cubas², Ángel Balaguer³, Bonaventura Casanova-Estruch², Baquero-Toledo Miguel⁴, Cháfer-Pericás Consuelo⁴
¹Instituto de Investigación Sanitaria La Fe - Valencia (Spain), ²Division of Neuroimmunology; University and Polytechnic Hospital La Fe - Valencia (Spain), ³Math faculty, Universitat de València - Valencia (Spain), ⁴Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe - Valencia (Spain)
- P103** **Evaluating the Performance of Plasma Phosphorylated-Tau 181 and Apolipoprotein E4 in Early Detection of Amyloid Pathology in a Multi-Center Study Reflective of Routine Clinical Practice**
Imke Kirste¹, Sayuri Hortsch², Sheila Baez-Torres³, Mercè Boada⁴, Monica Crane⁵, Frederiksen Kristian Steen⁶, Kevin Hanson⁷, Jonathan Liss⁸, Jeffrey Norton⁹, Marc Suárez-Calvet¹⁰, Craig Ritchie¹¹, Stephanie Rutrick¹², David Watson¹³, Kelley Yokum¹⁴, Clara Quijano-Rubio¹⁵
¹Roche Molecular Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³K2 Medical Research Maitland - Maitland (United States), ⁴ACE Alzheimer Center Barcelona - Barcelona (Spain), ⁵Genesis Neuroscience Clinic/Tennessee Memory Disorders Foundation - Knoxville (United States), ⁶Danish Dementia Research Centre, Department of Clinical Medicine - Copenhagen (Denmark), ⁷Eastside Research Associates - Redmond (United States), ⁸Columbus Memory Center - Columbus (United States), ⁹Charter Research Lady Lake - The Villages (United States), ¹⁰Barcelona Beta Brain Research Center - Barcelona (Spain), ¹¹Brain Health Scotland - Edinburgh (United Kingdom), ¹²Adams Clinical - Watertown (United States), ¹³Alzheimer's Research and Treatment Center - Wellington (United States), ¹⁴K2 Medical Research, LLC - Tampa (United States), ¹⁵Roche Diagnostics International Ltd - Rotkreuz (Switzerland)
- P104** **Plasma pTau181 and pTau217 similarly predict asymptomatic amyloid accumulation with performances comparable to amyloid-PET**
Steffi De Meyer¹, Jolien Schaefferbeke¹, Emma Luckett¹, Elena Blujdea², Patrick Dupont¹, Koen Van Laere³, Jeroen Vanbrabant⁴, Erik Stoops⁴, Eugene Vanmechelen⁴, Guglielmo Di Molfetta⁵, Henrik Zetterberg⁵, Nicholas Ashton⁵, Charlotte Teunissen⁶, Koen Poesen³, Rik Vandenbergh³
¹KU Leuven - Leuven (Belgium), ²UMC Amsterdam - Amsterdam (Netherlands), ³UZ Leuven - Leuven (Belgium), ⁴ADx NeuroSciences - Ghent (Belgium), ⁵Sahlgrenska Academy - Mölndal (Sweden), ⁶UMC Amsterdam - Amsterdam (Sweden)
- P105** **Use of Non- genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer's Disease. Further Biomarker Analysis and Implications for Use in Prevention.**
Paul Song¹, Clemente Humberto Zúñiga Gil², Blanca Isaura Acosta Gallo³, Cesar Alejandro Amescua³, Rufino Menchaca Díaz³, Sean Hong¹, Juan Mata¹, Katia Betito¹, Hank Lee¹, Yoonmi Kang¹, Lucia Hui¹
¹NKGen Biotech - Santa Ana (United States), ²Tijuana General Hospital - Tijuana (Mexico), ³Hospital Angeles - Tijuana (Mexico)
- P106** **Analytical validation of an ultrasensitive immunoassay for detection of phosphorylated Tau217 in human biofluids**
Jacqueline Surls¹, Kolby Janzen¹, Hannah Rawlins¹, Robyn Vega Ibanez¹, Lindsey Brown¹, Joshua Kemp¹
¹Rules-Based Medicine, a Q Squared Solutions Company - Austin (United States)
- P107** **Plasma p-tau217 Concentrations in Patients Undergoing Evaluation for Anti-Amyloid Therapy**
Alicia Algeciras-Schimmich¹, Susan Ashrafzadeh Kian¹, Joshua Bornhorst¹, Daniel Figdore¹, Jonathan Graff-Radford¹, Ronald Petersen¹, Vijay Ramanan¹
¹Mayo Clinic - Rochester (United States)
- P109** **Association of plasma Aβ42/Aβ40 with brain amyloidosis and conversion to mild cognitive impairment after a 5-year follow-up in individuals with subjective cognitive decline: data from the FACEHL cohort.**
José Antonio Allué¹, María Pascual-Lucas¹, Leticia Sarasa¹, Noelia Fandos¹, Jorge Loscos¹, Juan Pablo Tartari², Ángela Sanabria^{2,3}, Montserrat Alegret², Óscar Sotolongo-Grau², Lluís Tàrraga^{2,3}, Agustín Ruiz^{2,3}, María Eugenia Sáez⁴, Marta Marquie^{2,3}, Jose Terencio^{1,5}, Mercè Boada^{2,3}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya - Barcelona (Spain), ³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases. National Institute of Health Carlos III - Madrid (Spain), ⁴CAEBI, Centro Andaluz de Estudios Bioinformáticos - Sevilla (Spain), ⁵Grifols S.A. - Barcelona (Spain)



- P110** **Prediction of Alzheimer's disease using an AI driven screening platform: PREDICTOM study design**
Anna-Katharine Brem¹, Zunera Khan¹, Mark Ashworth¹, Nicholas Ashton¹, Sigurd Brandt², Anne Corbett³, Ana Diaz⁴, Holger Fröhlich⁵, Martha Therese Gjesten⁶, Dianne Gove⁴, Sandeep Kaushik⁷, Gaby Marquardt⁸, Matthias Müllenborn⁹, Spiros Nikolopoulos¹⁰, Dag Aarsland¹
¹King's College London - London (United Kingdom), ²GN Hearing - Copenhagen (Denmark), ³University of Exeter - Exeter (United Kingdom), ⁴Alzheimer Europe - Luxembourg (Luxembourg), ⁵Fraunhofer SCAI - Bonn (Germany), ⁶Stavanger University - Stavanger (Norway), ⁷Alzheimer GE Healthcare - Munich (Germany), ⁸Siemens Healthineers - Erlangen (Germany), ⁹Novo Nordisk - Copenhagen (Denmark), ¹⁰CERTH - Thessaloniki (Denmark)
- P111** **Cerebrospinal fluid levels of VAMP-2 and SNAP-25 are associated with executive function in dementia with Lewy bodies, an effect that is confounded by Alzheimer comorbidity**
Alba Cervantes González^{1,2}, Julie Goossens³, Nele Dewit⁴, Laia Lidón^{1,2}, Danna Perlaza^{1,2}, Juan Fortea^{1,2}, Daniel Alcolea^{1,2}, Alberto Lleó^{1,2}, Eugenia Vanmechelen³, Olivia Belbin^{1,2}
¹Sant Pau Memory Unit, Neurology Department and IIB-Sant Pau, Hospital de La Santa Creu i Santa Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), ²Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), - Madrid (Spain), ³ADx NeuroSciences NV, Zwijnaarde - Ghent (Belgium), ⁴Medpace Reference Laboratories (A.A.), Flow Cytometry Unit - Louvain (Belgium)
- P112** **A panel of CSF biomarkers reflecting inflammation, proteolysis and lipid transport to detect patients with amyloidosis and who will progress among cognitively unimpaired individuals.**
Charlotte Elisabeth Teunissen¹, Marta Del Campo²
¹Amsterdam UMC - Amersfoort (Netherlands), ²Barcelona beta - Barcelona (Spain)
- P113** **Novel plasma assay for p-Tau217: Evaluation in a cohort of individuals with cerebral amyloidosis and Alzheimer's disease.**
 Etienne Mondesert¹, Anne Marie Dupuy¹, Paul Wynveen², Corey Carlson², Miklos Szabo², Kevin Ley², Chris Knutson², Jean-Sebastien Blanchet³, Constance Delaby¹, Germain Busto⁴, Christophe Hirtz¹, Jean-Paul Cristol⁵, Sylvain Lehmann¹
¹LBPC-PPC, Univ Montpellier, CHU Montpellier, INM INSERM, Montpellier, France - Montpellier (France), ²Beckman Coulter Diagnostics - Chaska (United States), ³Beckman Coulter France - Villepinte (France), ⁴CMRR, Univ Montpellier, CHU Montpellier, INM INSERM - Montpellier (France), ⁵Biochimie Lapeyronie, Univ Montpellier, CHU Montpellier - Montpellier (France)
- P114** **Plasma p-tau217 measurement as a screening tool for future AD neuropathology proxy status in dementia-free individuals from the British 1946 birth cohort**
Ashvini Keshavan¹, William Coath¹, David M. Cash¹, Frederik Barkhof^{2,3,4}, Amanda Heslegrave⁵, Henrik Zetterberg^{5,6,7,8}, Jonathan M. Schott¹
¹Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), ²Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre - Amsterdam (Netherlands), ³Centre for Medical Image Computing, University College London - London (United Kingdom), ⁴Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square - London (United Kingdom), ⁵UK Dementia Research Institute, University College London, London - London (United Kingdom), ⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ⁷Hong Kong Center for Neurodegenerative Diseases, Science Park - Hong Kong (China), ⁸School of Medicine and Public Health, University of Wisconsin-Madison - Madison, Wisconsin (United States)
- P115** **Levels of p-tau217 in blood and its capacity to predict patterns change of cognitive trajectories in elderly: 10 years follow-up Valdecas Project.**
Elizabeth Valeriano Lorenzo^{1,2}, Sonia Wagner¹, David García³, Alicia Ruiz¹, Ana Belén Pastor¹, Belén Frades¹, Meritxell Valentí¹, Mario Ricciardi¹, Maria Ascension Zea¹, Marta Antón¹, Teodoro Del Ser¹, Pascual Sánchez-Juan¹
¹Fundación CIEN - Madrid (Spain), ²Universidad Autónoma de Madrid - Madrid (Spain), ³Universidad Complutense de Madrid - Madrid (Spain)
- P116** **Using neural derived EV-bound biomarkers in blood for the accurate classification of alpha synuclein aggregation in the brain**
Nicholas Rui Yuan Ho¹, Rasheed Samat¹, Gladys Ho¹, Peter Maimonis², Mario Morken², Marc Cantillon²
¹Sunbird Bio - Singapore (Singapore), ²Sunbird Bio - Cambridge, MA (United States)
- P117** **Plasma pTau181 predicts clinical progression in mild Alzheimer's Disease in a randomized controlled trial**
Dana Hilt¹, Jack Taylor¹, Mark Jaros², Christopher Chen³, John Harrison^{4,5,6}
¹Actinogen Medical - Sydney (Australia), ²Summit Analytical - Chicago (United States), ³Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁴Scottish Brain Sciences, Edinburgh, United Kingdom - Edinburgh (United Kingdom), ⁵King's College - London (United Kingdom), ⁶Alzheimercentrum, AUMC - Amsterdam (Netherlands)
- P118** **Introduction of multi-dimension biomarkers application for a randomized, double-blind, single-simulated clinical trial of sodium oligomannate on Alzheimer's disease**
Wang Qiong¹, Dai Linbin², Gao Feng², Shi Jiong², Shen Yong²
¹The first Affiliated Hospital of USTC - Hefei (China), ²The first Affiliated hospital of USTC - Hefei (China)
- P119** **Plasma p-tau and Amyloid biomarkers discrimination accuracy of biologically-defined Alzheimer's disease in a memory clinic setting: a head-to-head study**
Federica Anastasi¹, Aida Fernández-Lebrero¹, Nicholas J. Ashton², Paula Ortiz-Romero¹, Esther Jiménez-Moyano¹, Javier Torres-Torronteras¹, Marta Milà-Alomà¹, José Contador¹, Greta García-Escobar³, Oriol Grau-Rivera¹, Henrik Zetterberg², Marta Del Campo¹, Kaj Blennow², Albert Puig-Pijoan³, Marc Suárez-Calvet¹
¹BarcelonaBeta Brain Research Center - Barcelona (Spain), ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), ³Hospital del Mar Research Institute, Barcelona, Spain

- P120 Associations of dementia risk scores with glucose and lipid-related metabolic blood biomarkers in the persons at-risk of dementia**
Sabsil Ana Lopez Rocha ¹, Ruth Stephen ¹, Alina Solomon ², Tiia Ngandu ³, Jenni Lehtisalo ³, Tiina Laatikainen ³, Patrizia Mecocci ⁴, Jaakko Tuomilehto ⁵, Miia Kivipelto ¹, Francesca Mangialasche ¹
¹Karolinska Institutet - Stockholm (Sweden), ²University of Eastern Finland - Kuopio (Finland), ³Finnish Institute for Health and Welfare - Helsinki (Finland), ⁴Università di Perugia - Perugia (Italy), ⁵University of Helsinki - Helsinki (Finland)
- P121 Acceleration of epigenetic age as a biomarker for cognitive impairment: findings from the Diet and Healthy Aging cohort**
Kaisy Ye ¹
¹National University of Singapore - Singapore (Singapore)
- P122 The clinical impact of blood-based biomarkers: the PLASMAR study**
Gianmarco Iaccarino ^{1,2}, José Miguel Contador ^{1,3,4}, Isabel Estragués ^{5,3,6}, Leydi Dayana Martinez ^{7,4,3}, Aida Fernandez Lobero ^{5,8,3}, Irene Navalpotro-Gomez ⁵, Greta García-Escobar ³, Rosa Maria Manero ⁹, Oriol Grau-Rivera ^{5,4,10}, Juan Jose Hernandez-Sanchez ¹¹, Anna Padrós-Fluvià ¹¹, Paula Ortiz-Romero ⁵, Javier Torres-Torronteras ⁵, Marta Del Campo ^{5,12,3}, Albert Puig-Pijoan ^{3,4}, Marc Suárez-Calvet ^{5,3,4,10}
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain) - Barcelona (Spain), ²Università Campus Bio-Medico - Roma (Italy), ³Hospital del Mar Research Institute - Barcelona (Spain), ⁴Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ⁵BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ⁶Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ⁷BarcelonaBeta Brain Research Center (BBRC) - Barcelona (Spain), ⁸Cognitive Decline and Movement Disorders Unit, Neurology Department - Barcelona (Spain), ⁹Hospital del Mar Research Institute - Barcelona (Spain) - Barcelona (Spain), ¹⁰Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), ¹¹Laboratori de Referència de Catalunya - Barcelona (Spain), ¹²Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities - Madrid (Spain)
- P123 Is serum p-tau217 a viable blood source as a biomarker for Alzheimer's disease?**
Andrea L. Benedet ¹, Burak Arslan ¹, Kubra Tan ¹, Hanna Hulbert ¹, Ilaria Pola ¹, Guglielmo Di Molfetta ¹, Kaj Blennow ¹, Henrik Zetterberg ¹, Nicholas J. Ashton ²
¹Gothenburg University - Gothenburg (Sweden), ²Banner Health - Phoenix (United States)
- P125 Plasma p-tau217 as a pre-screening tool for clinical trials in asymptomatic and symptomatic individuals with Aβ pathology**
Pamela C L Ferreira ¹, Guilherme Povala ¹, Bruna Bellaver ¹, Guilherme Bauer-Negrini ¹, Firoza Lussier ¹, Chang Hyung Hong ², Hyun Woong Rho ², Dana L Tudorascu ¹, Thomas K Karikari ¹, Beth Snitz ¹, Sterling C Johnson ³, Sang Joon Son ², Tharick Pascoal ¹
¹Department of Psychiatry, School of medicine, University of Pittsburgh - Pittsburgh (United States), ²Department of Psychiatry, Ajou University School of Medicine - Sowon (Korea, Republic of), ³Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States)
- P126 Associations between Cognitive Impairment, ApoE genotype and Plasma p-tau Biomarkers in European MCI Populations: Insights from the AI-Mind Project**
Guido Maria Giuffrè ^{1,2}, Ana Perez ³, Soraya Alfonsin ^{4,5}, Christoffer Hatlestad-Hall ³, Timo Saarinen ⁶, Naike Caraglia ¹, Erik Christensen ⁷, Gwendlyn Kollmorgen ⁸, Kaj Blennow ^{9,10}, Henrik Zetterberg ^{9,10}, Fernando Maestú ^{4,5}, Hanna Renvall ^{6,11}, Ira Hebold Haraldsen ³, Paolo Maria Rossini ¹², Camillo Marra ^{1,2}
¹Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ²Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), ³Department of Neurology, Oslo University Hospital - Oslo (Norway), ⁴Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁵Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Pozuelo De Alarcón (Spain), ⁶BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁷Pre Diagnostics AS - Oslo (Norway), ⁸Roche Diagnostics GmbH - Penzberg (Germany), ⁹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹¹Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), ¹²Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)
- P127 Fully automated ultrasensitive Simoa assay for brain-derived tau: enhancing the characterization of Alzheimer's disease-related neurodegeneration in blood**
Jing Shi ¹, Casey Sheehy ¹, Julio Herrera ¹, David Wilson ¹, Prasad Gawande ¹, Mike Miller ¹, Kishore Malyavantham ¹
¹Quanterix - Billerica (United States)
- P128 Evaluation of the effects of repeated lumbar punctures on Alzheimer's Disease CSF and blood biomarkers**
Anne Biever ¹, Yixuan Zou ¹, Cassandra Arneja ¹, Schauer Stephen ¹, Calderon Emilia ¹, Cenicerio Ryan ¹, Gwendlyn Kollmorgen ², Tobias Bittner ³, Lyle Jew ⁴, Thomas Kremer ³, Venissa Machado ³, Bastian Zinnhardt ³, Cross Nicholas ⁵, Kaj Blennow ⁶, Edmond Teng ¹
¹Genentech Inc - San Francisco (United States), ²Roche Diagnostics - Penzberg (Germany), ³Roche - Basel (Switzerland), ⁴Genentech Inc - San Francisco (Switzerland), ⁵New Zealand Clinical Research - Christchurch (New Zealand), ⁶Department of Psychiatry and Neurochemistry - Gothenburg (Sweden)
- P129 Concordance between the updated Elecsys CSF immunoassays and amyloid PET for the diagnosis of Alzheimer's disease: Findings from the Apollo study**
Henrik Schinke ¹, Magnus Förnvik Jonsson ^{2,3}, Mayme Gummesson ², Rikard Nilsson ², Stefanie Gaupp ¹, Ekaterina Manuilova ¹, Silja McIlwrick ¹, Margherita Carboni ⁴, Erik Stomrud ^{5,6}
¹Roche Diagnostics GmbH - Penzberg (Germany), ²Department of Clinical Chemistry and Pharmacology, Skåne University Hospital - Lund (Sweden), ³Department of translational medicine, Lund university - Lund (Sweden), ⁴Roche Diagnostics Int. AG - Rotkreuz (Switzerland), ⁵Clinical, Memory Research Unit, Department of Clinical Sciences Malmö - Malmö (Sweden), ⁶Memory Clinic, Skåne University Hospital - Malmö (Sweden)

- P130** **Unraveling the Enigma in Cerebral Amyloid Angiopathy, Plasma Alzheimer's Downstream Markers, and Cognitive Decline: in relation to amyloid uptakes**
Sung Hoon Kang¹, Eun Hye Lee², Jun Pyo Kim², Sang Won Seo²
¹Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of)
- P131** **Detection of Cerebral Amyloid Angiopathy (CAA) in Alzheimer's Disease (AD) using blood biomarkers.**
Mario Ricciardi¹, Elizabeth Valeriano-Lorenzo¹, María Ascensión Zea-Sevilla¹, Meritxell Valentí¹, Belén Frades¹, Alicia Ruiz-González¹, Ana Belén Pastor¹, Francisco López-González¹, Paloma Ruiz¹, Laura Saiz¹, Iván Burgueño-García¹, María José López-Martínez¹, Alberto Rábano¹, Teodoro Del Ser¹, Pascual Sánchez-Juan¹
¹Alzheimer's Centre Reina Sofía-CIEN Foundation-ISCIII - Madrid (Spain)
- P132** **Davos Alzheimer's Collaborative Healthcare System Preparedness: Accurate Diagnosis Project Methodology**
Amy Deckert¹, Katherine J. Selzler¹, Monica Zigman Suchsland¹, Tim Macleod¹, Alissa Kurzman¹, Karen Weyrauch¹
¹Davos Alzheimer's Collaborative - Wayne (United States)
- P133** **Preliminary evaluation of plasma ALZpath p-tau217 for detecting amyloid pathology in a diverse community-based cohort**
Michelle Mielke¹
¹Wake Forest University School of Medicine - Winston Salem (United States)
- P134** **Advancing Detection of Neurological Biomarkers in Blood Using a Novel Ultrasensitive Single Molecule Counting Technology**
Renee Tobias¹, Peter Wagner¹, Johanna Sandlund¹, Kazushige Moriyama², Masayasu Imaizumi², Yukina Kawada², Kumiko Hamano², Frank Zaugg¹, Gipshu Dave¹, Daigo Inaoka¹, Hayato Kimura¹, Ko Kobayashi¹, Valerie Brachet¹
¹Fluxus, Inc. - Sunnyvale (United States), ²Fujirebio, Inc. - Tokyo (Japan)
- P135** **A two-stage machine learning model predicts amyloid β positivity accurately and cost effectively**
Wenjun Zhu¹, Li Sun¹, So-Youn Shin¹, Joseph Donahue¹, Jeanne Latourelle¹
¹Aitia - Somerville (United States)
- P136** **Use of CSF sTREM2/total-tau ratio as a potential prognostic biomarker to identify fast progressors in early Alzheimer's disease**
Jennifer Sorinas¹, Neva Coello², Nicole Pezous², Edward Khokhlovich³, Alexandra Rogojina², Jelena Curcic¹, Harsha Kocherla², Kristin Hannesdottir³
¹Biomedical Research, Novartis - Basel (Switzerland), ²Novartis Pharma AG - Basel (Switzerland), ³Biomedical Research, Novartis - Cambridge (United States)
- P137** **Exploring the association between p-tau217 and performance-based digital assessment of cognitive functioning in mild cognitive impairment**
Ana Perez^{1,2}, Soraya Afonsin^{3,4}, Guido Giuffrè⁵, Erik Christensen^{6,2}, Fernando Maestú^{3,7}, Hanna Renvall^{8,4}, Camillo Marra⁵, Paolo Rossini⁹, Christoffer Hatlestad-Hall¹, Ira Haraldsen^{1,10}
¹Department of Neurology, Oslo University Hospital - Oslo (Norway), ²Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), ³Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁴Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), ⁵Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁶Pre Diagnostics AS - Oslo (Norway), ⁷BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, - Helsinki (Finland), ⁸Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), ⁹Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy), ¹⁰Institute of Clinical Medicine, Faculty of Medicine, University of Oslo - Oslo (Norway)
- P138** **New high-throughput, fully automated immunoassay for plasma neurofilament light chain**
Jeff Todtleben¹, Dusten Unruh¹, Miklos Szabo¹, Corey Carlson¹, Kara Curtis¹, Katie Hoffmann¹, Laura Mediger¹, James Mendoza¹, Mikaela Nichova-Doseva¹
¹Beckman Coulter Inc - Chaska, Mn (United States)
- P139** **2-Step multi-marker algorithm to reduce the intermediate range of a high accuracy plasma p-Tau 217 test for amyloid detection**
David Wilson¹, Meenakshi Khare¹, Michele Wolfe¹, Patrick Sheehy¹, Karen Copeland², Lyndal Hesterberg³, Ann-Jeanette Vasco¹, Mike Miller¹
¹Quanterix - Billerica (United States), ²Boulder Statistics - Steamboat Springs (United States), ³HCS, Inc - Denver (United States)
- P140** **The diagnostic impact of plasma p-tau217 combined with structural magnetic resonance imaging in a memory clinic cohort.**
Jonas Jarholm^{1,2}, Sandra Tecelão¹, Bjørn-Eivind Kirsebom^{3,4}, Fernando Gonzalez-Ortiz^{5,6}, Lene Pålhaugen^{1,2}, Berglind Gísladóttir¹, Henrik Zetterberg⁵, Kaj Blennow^{5,6,9,10}, Per Selnes^{1,2}, Tormod Fladby^{1,2}
¹Department of Neurology, Akershus University Hospital - Lørenskog (Norway), ²Institute for Clinical Medicine, University of Oslo - Oslo (Norway), ³Department of Neurology, University Hospital of North Norway - Tromsø (Norway), ⁴Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway - Tromsø (Norway), ⁵Inst. of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), ⁶Clinical Neurochemistry Lab, Sahlgrenska University Hospital - Mölndal (Sweden), ⁷Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), ⁸UK Dementia Research Institute at UCL - London (United Kingdom), ⁹Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University - Paris (France), ¹⁰Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (China)
- P141** **Geographic Access to Amyloid PET Scans in the U.S.: Implications for Clinical Trials and Real-World Treatment**
Mark Hanson¹, Ying Liu¹, Hao Yin¹, Soeren Matke¹
¹University of Southern California - Los Angeles (United States)
- P142** **Implementation of p-tau181/A β 42 and total-tau/A β 42 Roche Elecsys ratios: Evaluation of cut-offs for p-tau181, total-tau and A β 42**
Jessica Colon-Franco¹, Lynn Bekris², Sarah Zilka¹, Katie Troike¹, Maria Khrestian², Tousi Babak³, Elizabeth Tuason², James Leverenz³
¹Laboratory Medicine, Diagnostic Institute, Cleveland Clinic - Cleveland (United States), ²Genomic Medicine Institute, Cleveland Clinic - Cleveland (United States), ³Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic - Cleveland (United States)

POSTER PRESENTATIONS

- P143 **Exploring the utility of plasma microRNA for early diagnosis of Alzheimer's disease.**
Joanna Williams¹, Diane Guevremont¹, Chris Fowler², Colin Masters², Ralph Martins³, Wickliffe Abraham¹, Warren Tate¹, Nicholas Cutfield¹
¹University of Otago - Dunedin (New Zealand), ²The Florey Institute - Melbourne (Australia), ³Macquarie University - New South Wales (Australia)
- P144 **The Plasma pTau181/217 ratio is highly sensitive to discriminate Alzheimer's disease from other dementias – a pilot study in a memory clinic population**
Michaela Defrancesco¹, Alex Hofer¹, Christian Humpel¹
¹Medical University of Innsbruck - Innsbruck (Austria)

THEME 12: Proof of concept/Translational research for Alzheimer Drug Development interventions

- P145 **APOE-Targeted Epigenome Therapy for Alzheimer's Disease**
 Boris Kantor¹, Bernadette O'donovan¹, Elena Korsakova², Joseph Rittiner¹, Elaine Hamm², Ornit Chiba-Falek¹
¹Duke - Durham (United States), ²CLAIRigene - Durham (United States)
- P146 **Nasal Immunotherapy clears intracellular tau pathology through TRIM21 and improves cognitive functions in aged tauopathy mice**
Rakez Kaye¹
¹University of Texas Medical Branch - Galveston (United States)
- P147 **Unlocking Alzheimer's: Exploring NLBP3 Inhibitors for Innovative Alzheimer disease Therapy**
Prabhakar Tiwari¹, Kaushik Meenakshi¹, Dwivedi Rekha¹, Tripathi Manjari¹, Yadav Awesh Kumar², Singh Rakesh²
¹All India Institute of medical sciences - New Delhi (India), ²National Institute of Pharmaceutical Education and Research (NIPER), Rae Bareilly - Raebareilly (India)
- P148 **Brain Health Services for the prevention of dementia: evidence from pilot experiences**
Federica Ribaldi¹, Giovanni B Frisoni¹
¹UNIGE - Geneva (Switzerland)
- P149 **De novo designed Tfr1 binding peptide to shuttle antibody therapeutics across blood brain barrier**
Hao Wu¹, Yibo Qiu¹, Fei Sheng¹, Yue Wu¹
¹ChainGen Bio - Shanghai (China)
- P150 **Tau PET Measures Optimized for Detecting Treatment Effects on Tau Spread in Alzheimer Disease**
 Janice Wong¹, Tina Wang², Ritabrato Datta², Dave Henley^{3,4}, Hartmuth C. Kolb², Ziad S. Saad²
¹Janssen Research & Development, LLC - Cambridge, Massachusetts (United States), ²Janssen Research & Development, LLC - La Jolla, California (United States), ³Janssen Research & Development, LLC - Titusville, New Jersey (United States), ⁴Indiana University School of Medicine, Psychiatry - Indianapolis, Indiana (United Kingdom)
- P151 **Prediction of cognitive outcome and progression to dementia using Polyunsaturated fatty acids Omega6/3 ratio**
Victor Andrade^{1,2}, Luca Kleinedam^{3,4}, Holger Wagner-Thelen⁵, Rafael Campos⁵, Tommaso Ballarini^{2,6}, Sarah Egert⁷, Pamela Martino-Adami¹, Leonie Weinhold⁸, Sophie Guyonnet⁹, Bruno Vellas¹⁰, Frank Jessen^{6,11}, Matthias Schmid^{8,6}, Anja Schneider^{4,6}, Michael Wagner^{4,6}, Alfredo Ramirez^{1,2}
¹Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty Köln (Germany), ²Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn - Bonn (Germany), ³Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty - Köln (Germany), ⁴Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn - Bonn (Germany), ⁵Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty - Köln (Germany), ⁶DZNE - Bonn (Germany), ⁷Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn - Bonn (Germany), ⁸Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn - Bonn (Germany), ⁹Centre d'Epidémiologie et de Recherche en santé des POPulations de Toulouse - Toulouse (France), ¹⁰Gérontopôle, Toulouse University Hospital - Toulouse (France), ¹¹Department of Psychiatry, Medical Faculty, University of Cologne - Köln (Germany)
- P152 **MRI monitoring of Alzheimer disease patients in the new era of disease-modifying therapies: a real-world case study**
Salvatore Napoli¹, Celine Maes², Rafay Khan², An Tanghe², Silvina Catuara Solarz², Jill Claes², Nuno Pedrosa De Barros², Diana Sima², Wim Van Hecke², Dirk Smeets², Annemie Ribbens²
¹Neurology and Infusion Center of New England - Foxborough (United States), ²icometrix - Leuven (Belgium)
- P153 **Air pollution as a possible target to prevent Alzheimer disease: association of person-specific air pollutant exposure and related chemicals/metabolites with A/T/N biomarkers**
Chengjie Xiong¹, Ruijin Lu¹, Quoc Bui¹, Brent Popp¹, Suzanne Schindler¹, Leah Shriver¹, Carlos Cruchaga¹, Jason Hassenstab¹, Tammie Benzinger¹, Folasade Agboola¹, Emily Gremminger¹, Marissa Streitz¹, Charles Hall¹, Krista Moulder¹, John Morris¹
¹Washington University in St. Louis - St. Louis (United States)
- P154 **Mild behavioral impairment: building the killifish-mouse-human pipeline in the INSPIRE-t cohort.**
 Emmanuel Gonzalez-Bautista^{1,2,3}, Bruno Guiard^{3,4}, Isabelle Ader^{3,5}, Sophie Guyonnet^{3,2}, Jason Shourick⁶, Adelaide De Mauleon¹, Estelle Dubus¹, Marie Mommeja¹, Jean-Philippe Pradere^{3,5}, Maria Soto^{1,2,3}
¹Research and Clinical Alzheimer's Disease Center, CMRR, CHU Toulouse - Toulouse (France), ²Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier - Toulouse (France), ³IHU HealthAge, Inserm, CHU Toulouse - Toulouse (France), ⁴Equipe REMEMBeR. Centre de Recherches sur la Cognition Animale, CRCA, Univ. P. Sabatier - Toulouse (France), ⁵Institut RESTORE - UMR 1301 - Inserm/5070-CNRS/EFS/ Université Paul Sabatier - Toulouse (France), ⁶Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier - Toulouse (France)



- P155** **ADDITION-MCI: A clinical trial to fully exchange the blood plasma of older cognitively impaired individuals with young donor plasma.**
Sara Nygaard^{1,2}, Lana Nagmadin Karim³, Andreas Engvik⁴, Håkon Ihle-Hansen⁵, Petter Holland¹, Arne Sørås¹
¹Dept. of Microbiology, Oslo University Hospital - Oslo (Norway), ²Dept. of Acute Medicine, Oslo University Hospital - Oslo (Norway), ³Dept. of Immunology and Transfusion Medicine, Oslo University Hospital - Oslo (Norway), ⁴Dept. of Endocrinology, Obesity and Preventive Medicine, Oslo University Hospital - Oslo (Norway), ⁵Dept of Medicine, Bærum Hospital, Vestre Viken Hospital Trust - Drammen (Norway)
- P156** **Fibrinogen as a Key Binding Partner in Human Plasma for Lecanemab Biosimilar IgG**
Lei Liu¹, Jean-Pierre Bellier¹, Andrea Roman¹, Caitlyn Christiano¹, Juliana Anzai¹, Stephanie Moreno¹, Emily Campbell¹, Lucas Godwin¹, Amy Li¹, Alan Chen¹, Sarah Alam¹, Adrianna Saba¹, Han Bin Yoo¹, Hyun-Sik Yang¹, Jasmeer Chhatwal¹, Dennis Selkoe¹
¹Brigham and Women's Hospital - Cambridge (United States)
- P157** **Implantable device for intrathecal pseudodelivery of immunotherapies: preclinical testing of a prototype for humans**
 Ester Perez-Martin¹, Maria Rodriguez-Cañon¹, Gabriel Alvarez¹, Catuxa Prado¹, Cristina Tomas-Zapico^{2,3}, Manuel Menendez-Gonzalez^{2,3,4}
¹Neuroscience Innovative Technologies - Llanera (Spain), ²Universidad de Oviedo - Oviedo (Spain), ³Instituto de Investigación Sanitaria del Principado de Asturias - Oviedo (Spain), ⁴Hospital Universitario Central de Asturias - Oviedo (Spain)
- P158** **ONESTX-01, a potent inhibitor of Steroid Sulphatase (STS), that restores neuron cholinergic activity and decreases cognitive impairment: design of a phase IIa clinical study.**
Viñas Andrés-Simón¹, Javier Valle-Galisteo², Juan Antonio Fernández-Cabrera³, Almudena Ramos-Pozo², José María Hernández-Curiel³, Sandra Gavaldá-Martín¹, Cristina García-Gutierrez², Inés Sánchez Romero³, Mercedes Pérez-Jiménez², Elena Rodríguez Sandoval³, Antonio Aires-Trapote¹, Manuel Jesús Muñoz-Ruiz², Ángel Manuel Carrión³, Ángel Cebolla-Ramírez¹
¹Olavide Neuron STX SL - Seville (Spain), ²Universidad Pablo de Olavide, Centro Andaluz de Biología del Desarrollo (CABD), CSIC, JA - Seville (Spain), ³Universidad Pablo de Olavide, Department of Physiology, Anatomy and Cellular Biology - Seville (Spain)
- P159** **Novel Cyclodextrins with Reduced Cellular Toxicity: Application in Treating Pathologic Tau-Related Lipid Accumulations**
Ji-Yeong Lee¹, Heegon Kim², Sun Ah Park^{1,3,4}
¹Lab of Neurodegenerative Dementia, Department of Anatomy, Ajou University School of Medicine - Suwon (Korea, Republic of), ²Renatus - Daejeon (Korea, Republic of), ³Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University Graduate School of Medicine, - Suwon (Korea, Republic of), ⁴Department of Neurology, Ajou University School of Medicine - Suwon (Korea, Republic of)
- P160** **Enhanced Imaging Techniques for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's Disease**
Jude-Patrick N. Okafor¹, Jacob Stefanko¹, Hope Shimony¹, Austin McCullough¹, Nayid Jana¹, Nelly Joseph-Mathurin¹, Stephen Jarman¹, Edmond Knopp², Tammie Benzinger¹
¹Washington University School of Medicine - Saint Louis (United States), ²Hyperfine Inc. - Guilford (United States)
-  **P161** **Targeting the Bullseye: Leveraging Molecular Subtypes and Repurposed Drugs for Personalized AD Treatment**
Sahaj Vaidya¹, Lavan KJ²
¹New Jersey Institute of Technology - Newark (United States), ²Brain Matrix Alliance - Dubai (United Arab Emirates)

THEME 15: Clinical trials Early Career Investigator Showcase

- P162** **PET Imaging of Microtubules in Cognitively Normal and Impaired Older Adults: A Pilot Study**
 Bhuvanachandra Bhoopal¹, Mack Miller¹, Naresh Damuka¹, Krishna Gollapelli¹, Ivan Krizan¹, Samuel Lockhart¹, Akiva Mintz², Suzanne Craft¹, Kiran K Solingapuram Sai¹
¹Wake Forest School of Medicine - Winston Salem (United States), ²Columbia University School of Medicine - New York (United States)

POSTER SESSION 3: From Friday, November 1 - 7:15 a.m. to Friday, November 1 - 5:00 p.m.

THEME 5: Clinical trials: Cognitive and functional endpoints

- P163** **Impairments of visual information processing in dementia**
Mark Stemmler¹, Monika Daseking²
¹Friedrich-Alexander University of Erlangen-Nuremberg - Erlangen (Germany), ²Helmut-Schmidt-University Hamburg - Hamburg (Germany)
- P164** **Home-based transcranial alternating current stimulation over the precuneus in Alzheimer's disease: a double-blind, randomized, placebo-controlled trial followed by an open label phase**
 Valentina Cantoni¹, Elias Paolo Casula², Chiara Cupidi³, Daniele Altomare⁴, Enrico Premi⁵, Elisa Zummo³, Romina Esposito², Nadine Huber⁶, Eino Solje^{7,8}, Maria Sofia Cotelli¹, Alessandro Martorana⁹, Giacomo Koch^{2,10,11}, Annakaisa Haapasalo¹², Alberto Benussi¹³, Barbara Borroni^{1,10}
¹Department of Continuity of Care and Frailty, ASST Spedali Civili of Brescia - Brescia (Italy), ²Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Rome (Italy), ³Neurology Unit, Fondazione Istituto G. Giglio - Cefalù (Italy), ⁴Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Brescia (Italy), ⁵Stroke Unit, ASST Spedali Civili of Brescia - Brescia (Italy), ⁶A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, - Kuopio (Finland), ⁷Institute of Clinical Medicine, University of Eastern Finland, - Kuopio (Finland), ⁸Neuro center, Neurology - Kuopio (Finland), ⁹Department of Systems Medicine, Memory Clinic, University of Rome Tor Vergata, - Rome (Italy), ¹⁰Department of Clinical and Experimental Sciences, University of Brescia - Brescia (Italy), ¹¹Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy), ¹²A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio (Finland), ¹³Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste - Trieste (Italy)
- P165** **Assessing informal caregivers' self-perceived sense of competence in Mild Cognitive Impairment: Psychometric evaluation of the 7-item Sense of Competence Questionnaire (SCQ)**
Pascual Sanchez-Juan¹, Elena Garcia-Arcelay², Mircea Balasa³, Gerard Piñol-Ripoll⁴, Mercè Boada⁵, Lamberto Landete⁶, Eloisa Navarro⁷, Inmaculada Abellán⁸, Angel Berbel⁹, Beatriz Espejo¹⁰, Mariló Almagro¹¹, Jesús Rodrigo¹¹, Jorge Maurino², Sagrario Manzano-Palomo⁷, Javier Ballesteros¹²
¹Fundación CIEN - Madrid (Spain), ²Roche Farma - Madrid (Spain), ³Hospital Clínic, IDIBAPS - Barcelona (Spain), ⁴IRBLLeida - Lleida (Spain), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁶Hospital Universitario Dr. Peset - Valencia (Spain), ⁷Hospital Universitario Infanta Leonor, - Madrid (Spain), ⁸Hospital San Vicente del Raspeig, - Alicante (Spain), ⁹Hospital de la Cruz Roja Madrid - Madrid (Spain), ¹⁰Unit Hospital Clínico San Cecilio - Granada (Spain), ¹¹CEAFA - Madrid (Spain), ¹²UPV/EHU, CIBERSAM - Leioa (Spain)
- P166** **The effect of high-definition transcranial direct current stimulation (HD-tDCS) on cognitive function in patients with mild cognitive impairment: a randomized, triple-blind, sham-controlled, study**
Che-Sheng Chu¹, Chih-Chuan Pan¹, Cheng-Ho Chang¹, Yung-Chih Chiang¹, Hsin-Ya Kuo¹, Shiou-Lan Chen², Cheng-Sheng Chen²
¹Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China), ²Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China)
- P167** **The longitudinal relationship between cardiorespiratory fitness, amyloid- β , and cognitive performance in adults at risk for Alzheimer's disease.**
Adam J. Paulsen^{1,2}, Brianne M. Breidenbach^{1,2}, Matthew Glittenberg^{1,2}, Sanjay Asthana^{1,2,4}, Sterling C. Johnson^{1,2}, Tobey J. Bethausen¹, Dane B. Cook^{5,6}, Ozioma C. Okonkwo^{1,2,4}
¹Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health - Madison (United States), ²Wisconsin Alzheimer's Institute, Madison - Madison (United States), ³Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital - Madison (United States), ⁴Department of Kinesiology, University of Wisconsin-Madison - Madison (United States), ⁵William S. Middleton Memorial Veterans Hospital - Madison (United States)
- P168** **Evaluating the Performance of Participant-Report, Study Partner-Report, and Performance-Based Assessments of Daily Functioning in Older Adults as Functional Endpoints in Alzheimer's Disease Clinical Trials**
 Hannah Truitt^{1,2}, Rebecca Amariglio^{1,3,2}, Sharon Wang³, Onyinye Udeogu³, Ariel Brathwaite³, Dorene Rentz^{1,2}, Gad Marshall^{1,3,2}, Mark Dubbelman^{1,3,2}
¹Brigham and Women's Hospital - Boston (United States), ²Harvard Medical School - Boston (United States), ³Massachusetts General Hospital - Boston (United States)
- P169** **Mapping Alzheimer's disease progression via changes in the CDR-Global for accurate clinical trial design**
Rodrigo Canovas¹, Christopher Fowler², Simon Laws^{3,4,5,6}, Stephanie Rainey-Smith^{7,8,9,10}, Colin Masters², Ralph Martins^{7,11}, Paul Maruff², James Doecke¹²
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²Florey Institute, The University of Melbourne - Parkville (Australia), ³Centre for Precision Health, Edith Cowan University - Joondalup (Australia), ⁴Collaborative Genomics and Translation Group, Edith Cowan University, - Joondalup (Australia), ⁵School of Medical and Health Sciences, Edith Cowan University, - Joondalup (Australia), ⁶Curtin Medical School, Curtin University - Bentley (Australia), ⁷School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ⁸School of Psychological Science, University of Western Australia - Crawley (Australia), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ¹⁰Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ¹¹Department of Biomedical Sciences, Macquarie University - Macquarie (Australia), ¹²Australian E-Health Research Centre, CSIRO - Herston (Australia)
- P170** **Time-saved due on treatment: validation in a real-world population study**
 Rodrigo Canovas¹, Marcela Cespedes², Christopher Fowler³, Stephanie Rainey-Smith^{4,5,6,7}, Colin Masters³, Ralph Martins^{4,8}, Paul Maruff³, James Doecke²
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²Australian E-Health Research Centre, CSIRO - Herston (Australia), ³Florey Institute, The University of Melbourne - Parkville (Australia), ⁴School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ⁵School of Psychological Science, University of Western Australia - Crawley (Australia), ⁶Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ⁷Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ⁸Department of Biomedical Sciences, Macquarie University - Macquarie (Australia)

- P171 Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning-Enabled Digital Cognitive Assessment**
Ali Jannati¹, Karl Thompson¹, Claudio Toro-Serey¹, Connor Higgins¹, Russell Banks¹, Pobst Jeff¹, Showalter John¹, Bates David¹, Tobyn Sean¹, Pascual-Leone Alvaro¹
¹Linus Health - Boston (United States)
- P173 Relationships of hypnotics with incident dementia and Alzheimer's disease: a longitudinal study and meta-analysis**
Jiahui Hou¹, Yiming Huang¹
¹Xuanwu Hospital, Capital Medical University, - Beijing (China)
- P174 Preliminary Findings on the Effects of Donepezil on Visuospatial Abilities in amyloid PET-positive Mild Cognitive Impairment Assessed Using Eye-Tracking**
Ko Woon Kim¹, Qi Wang², Su Jeong Wang³, Byoung-Soo Shin³
¹Jeonbuk National University Medical School and Hospita - Jeonju (Korea, Republic of), ²Jeonbuk National University Medical School - Jeonju (Korea, Republic of), ³Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
- P175 Understanding the Early Alzheimer's Disease Experience: Perspectives from Patients and Caregivers**
Jennifer Dine¹, Jae Lee², Anand Shewale², Jonathan Stokes², Bonita Basnyat¹, Michelle Brown¹, Amy Greenblatt¹, Elaheh Shirmeshan²
¹RTI International - Research Triangle Park (United States), ²AbbVie - North Chicago (United States)
- P176 Impact of Rater Change on Clinical Dementia Rating Data: A Retrospective Analysis**
David Miller¹, Xingmei Wang¹, Alan Kott²
¹Signant Health - Blue Bell, Pa (United States), ²Signant Health - Prague (Czech Republic)
- P177 A strategic approach to rigorous clinical endpoint strategies in drug development – An example from a phase 2 trial in early Alzheimer's disease (EXPLAIN-AD)**
Flavia Loreto¹, Alex Sverdllov², Nicole Pezous¹, Neva Coello¹, Alex Murphy³, Peggy Allred⁴, Peter Rock¹, Gul Erdemli³, Joann Whittle⁵, Jaffar Saleh Subaie⁶, Jon G. Snædal⁷, Jelena Curcic⁸, Kristin Hannesdottir⁴
¹Novartis - Basel (Switzerland), ²Novartis - East Hanover (United States), ³Novartis - Cambridge (United States), ⁴Novartis Biomedical Research - Cambridge (United States), ⁵Novartis Biomedical Research - Chicago (United States), ⁶Novartis - Mexico City (Mexico), ⁷National University Hospital of Iceland | LSH - Department of Geriatrics - Reykjavik (Iceland), ⁸Novartis Biomedical Research - Basel (Switzerland)

THEME 6: Cognitive assessment and clinical trials

- P178 Stakeholder-Informed Pragmatic Trial Protocol of the TabCAT-BHA for the Detection of Cognitive Impairment in Primary Care**
Huong Nguyen^{1,2}, Alissa Bernstein Sideman³, Annette Langer-Gould⁴, Eric Lee⁵, Soo Borson¹, Ernest Shen¹, Elena Tsoy³, Katherine Possin³
¹Kaiser Permanente Southern California - Pasadena (United States), ²Kaiser Permanente Bernard J Tyson School of Medicine, Department of Health Systems Science - Pasadena (United States), ³Department of Neurology, University of California, San Francisco - San Francisco (United States), ⁴Kaiser Permanente Southern California, Department of Research and Evaluation, Southern California Permanente Medical Group - Pasadena (United States), ⁵Kaiser Permanente Southern California, West Los Angeles Medical Center, Southern California Permanente Medical Group - Los Angeles (United States)
- P179 Transformation of Quality of Life of Alzheimer's disease Cases: Impact of Yoga**
Kaushik Meenakshi¹
¹All India Institute of Medical Sciences, New Delhi, India - Delhi (India)
- P180 Interpersonal Effects of ADRD Screening on older primary care patients and their family members wellbeing: Results from the Caregiver Outcomes of Alzheimer's Disease Screening (COADS) Trial**
Nicole Fowler¹, Yifan Lou², Christina Baucco³, Malaz Boustani¹, Joan Monin²
¹Indiana University School of Medicine - Indianapolis (United States), ²Yale University - New Haven (United States), ³IU Center for Aging Research - Indianapolis (United States)
- P181 Advancements in identifying stage 2 preclinical Alzheimer's disease: reliable methods to**
David López-Martos¹, Marc Suárez-Calvet¹, Armand González-Escalante¹, Marta Milà-Alomà¹, Juan Domingo Gispert¹, Carolina Minguillon¹, Clara Quijano-Rubio², Gwendlyn Kollmorgen³, Henrik Zetterberg⁴, Kaj Blennow⁴, Oriol Grau-Rivera¹, Gonzalo Sánchez-Benavides¹
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ²Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ³Roche Diagnostics GmbH - Penzberg (Germany), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden)
- P182 Identification of Cognitive Impairment in Alzheimer's Disease with Drawing and Speech-Based Assessments and Metrics**
Tanya Talkar¹, Karl Thompson¹, Ali Jannati^{1,2}, Russell Banks¹, John Showalter¹, David Bates¹, Alvaro Pascual-Leone^{1,2,3}, Sean Tobyn¹
¹Linus Health - Boston (United States), ²Department of Neurology, Harvard Medical School - Boston (United States), ³Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)

POSTER PRESENTATIONS

- P183** **CognoSpeak: an automatic, remote assessment of early cognitive decline in real-world conversational speech**
 Madhurananda Pahar ¹, Fuxiang Tao ¹, Bahman Mirheidari ¹, Nathan Pevy ¹, Rebecca Birght ², Swapnil Gadgil ², Lise Sproson ³, Dorota Braun ⁴, Caitlin Illingworth ⁴, Christensen Heidi ¹, Daniel Blackburn ⁴
¹University of Sheffield, ¹Department of Computer Science - Sheffield (United Kingdom), ²Therapy Box, London - London (United Kingdom), ³NIHR Devices for Dignity HTC - London (United Kingdom), ⁴Sheffield Institute for Translational Neuroscience} University of Sheffield, Sheffield - Sheffield (United Kingdom)
- P184** **The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Detect the Presence of Amyloid in Clinical Samples with Cognivue Clarity®**
 James Galvin ¹, Michael Kleiman ¹, Paul Estes ², Heather Harris ², Ernest Fung ²
¹University of Miami Miller School of Medicine - Boca Raton (United States), ²Cognivue, Inc - Victor (United States)
- P185** **Evaluating Cognition across Latin America: Insights from the LatAm-FINGERS Study**
 Lucía Crivelli ¹, Nicolás Corvalán ¹, Ricardo F. Allegri ¹, Ismael L. Calandri ¹, Paulo Caramelli ², Mark A. Espeland ³, Francisco Lopera ⁴, Ricardo Nitrini ⁵, Kathryn V Papp ⁶, Gustavo E. Seivler ¹, Rosa María Salinas ⁷, Ana Luisa Sosa ⁷, Claudia Kimie Suemoto ⁸, Monica Sanches Yassuda ⁹, Laura Baker ¹⁰
¹Fleni - Buenos Aires (Argentina), ²Faculty of Medicine - Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ³Departments of Internal Medicine and Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), ⁴Grupo de Neurociencias de Antioquia, Universidad de Antioquia - Medellín (Colombia), ⁵Cognitive and Behavioral Neurology Unit - University of São Paulo - São Paulo (Brazil), ⁶Brigham and Women's Hospital, Harvard Medical School - Massachusetts (United States), ⁷Dementias Laboratory, National Institute of Neurology and Neurosurgery - Ciudad De México (Mexico), ⁸Division of Geriatrics, Department of Internal Medicine, University of Sao Paulo Medical School - São Paulo (Brazil), ⁹University of São Paulo - São Paulo (Brazil), ¹⁰Wake Forest University School of Medicine - Winston-Salem, North Carolina (United States)
- P186** **Exploring the role of education on cognitive outcomes in Hispanic/Latino Adults in Southern California: Insights from Community Based Intervention, SERVE-OC**
 Alissa Kurzman ¹, Bruce Albala ¹, Aryanna Chavez ¹, Jeffrey Wing ², Desiree Gutierrez ³, Darnisha Draughter ³, Bernadette Boden-Albala ³
¹University of California Irvine - Irvine (United States), ²Ohio State University - Columbus (United States), ³University of California, Irvine - Irvine (United States)
- P187** **Longitudinally defined objective subtle memory decline in cognitively unimpaired individuals is associated with tau deposition in Braak I/II regions**
 Gonzalo Sánchez-Benavides ^{1,2,3}, David López-Martos ^{1,2}, Mahnaz Shekari ¹, Edilio Borroni ⁴, Gregory Klein ⁴, Matteo Tonietto ⁴, Marc Suarez-Calvet ^{1,2,3,5}, Juan Domingo Gispert ^{1,2}, Oriol Grau-Rivera ¹
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ²Hospital del Mar Medical Research Institute (IMIM) - Barcelona (Spain), ³Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), ⁴Roche Pharma Research and Early Development, Neuroscience and Rare Disease, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain)
- P188** **Severe COVID-19 leads to accelerated dementia onset**
 Sasha Mukhija ^{1,2,3}, Max Sunog ^{1,2}, Colin Magdamo ^{1,2}, Mark W. Albers ^{1,2}
¹Harvard Medical School - Boston (United States), ²Massachusetts General Hospital - Boston (United States), ³University Hospital of Zurich - Zurich (Switzerland)
- P189** **Effect of disease stage and amyloid level on harmonized data from neuropsychological tests in three natural history studies.**
 Rosita Shishegar ¹, Vincent Dore ¹, Pierrick Bourgea ², Simon Laws ³, Tenielle Porter ³, Samantha Burnham ⁴, Azadeh Feizpour ⁵, Michael Weiner ⁶, Jason Hassenstab ⁷, Christopher Row ⁵, Victor Villemagne ⁸, Colin Masters ⁵, Jürgen Fripp ², James Doecke ², Hamid Sohrabi ⁹, Paul Maruff ¹⁰
¹The Australian e-Health Research Centre, CSIRO - Melbourne (Australia), ²The Australian e-Health Research Centre, CSIRO - Brisbane (Australia), ³School of Biomedical Sciences, Faculty of Health Sciences, Curtin University - Perth (Australia), ⁴Avid, Eli Lilly and Company - Boston (United States), ⁵Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), ⁶Center for Imaging of Neurodegenerative Diseases, University of California-San Francisco - San Francisco, (United States), ⁷Institute of Clinical and Translational Sciences, Washington University School of Medicine - St Louis (United States), ⁸Department of Psychiatry, University of Pittsburgh - Pittsburgh (United States), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Perth (Australia), ¹⁰Cogstate Ltd - Melbourne (Australia)
- P190** **Comparing Summary and Underlying Cognitive Process Performance between ADAS-Cog and AVLT Wordlist Memory Tests**
 Jason Bock ^{1,2}, Junko Hara ^{1,3}, Dennis Fortier ¹, Tushar Mangrola ¹, Michael Lee ⁴
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine, ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach, ⁴Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States)
- P191** **ClinCloud Successfully Democratizes POLARIS-AD Phase 3 Early Alzheimer's Disease Study to Maximize Trial Exposure to Diversified and Underserved Populations**
 Maria Biban ¹, James Rock ², Jessica Branning ¹, Caroline Skirrow ³, Geraldine Marino ¹, Landon Estes ¹, Karem Sapp ¹, Natalie Gadea ¹
¹ClinCloud, LLC - Maitland (United States), ²AriBio Co., LTD - San Diego (United States), ³Novo LTD - London (United Kingdom)
- P192** **Associations between body composition metrics, Clinical Dementia Rating Scale (CDR®) scores, gender, and race/ethnicity among older adults with and without cognitive impairment**
 Giovanna Pilonieta ¹, David Geldmacher ¹
¹The University of Alabama at Birmingham - Birmingham (United States)
- P193** **Relationship between body composition metrics and performance on the Dementia Rating Scale (DRS-2) in older adults with and without cognitive impairment.**
 David Geldmacher ¹, Giovanna Pilonieta ¹
¹The University of Alabama at Birmingham - Birmingham (United States)

- P194** **Effects of the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program on Clinician Attitudes and Confidence**
Soeren Matthe¹, Tabasa Ozawa¹, Valeria Baldivieso², Otelo Corrêa Dos Santos Filho³, Ishtar Govia⁴, Hisatomo Kowa⁵, Mariana Lopez-Ortega⁶, Alison Mckean⁷, Amy Deckert⁸, Katherine Selzler⁸
¹University of Southern California - Los Angeles (United States), ²AdventHealth - Orlando (United States), ³State University of Rio de Janeiro - Rio De Janeiro (Brazil), ⁴Jamaica Mental Health Advocacy Network - Kingston (Jamaica), ⁵Kobe University - Kobe (Japan), ⁶National Institute of Geriatrics - Mexico City (Mexico), ⁷Brain Health Scotland - Edinburgh (United Kingdom), ⁸Davos Alzheimer's Collaborative - Wayne (United States)
- P195** **Davos Alzheimer's Collaborative Healthcare System Preparedness Early Detection Program: Key Roles for Successful DCA Implementation**
Amy Deckert¹, Katherine J. Selzler¹, Laura Chavira-Razo¹, Alissa Kurzman¹, Tim Macleod¹
¹Davos Alzheimer's Collaborative - Wayne (United States)
- P196** **Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) changes anchored with CDR progression in a preclinical AD population**
Catarina Cunha¹, Raymond Blattner¹, Barbara Echevarria¹, Selam Negash¹, Christopher Randolph¹
¹WCG Clinical Research Solution - Princeton (United States)
- P197** **An Assessment of the Utility of the Montreal Cognitive Assessment (MoCA) in predicting Amyloid PET Positivity in Alzheimer's Disease (AD) Clinical Trials**
Elizabeth Sosa¹
¹Irvine Clinical Research - Irvine (United States)
- P198** **Development and validation of a 4-years all-cause dementia prediction tool based on sleep-related symptoms using a score risk prediction model**
Hyukjun Lee¹, Ji Won Han¹, Jong Bin Bae¹, Dong Gyu Moon¹, Jin Shin², Dae Jong Oh³, Eunji Lim⁴, Bong Jo Kim⁵, Dong Woo Lee⁶, Jeong Lan Kim⁷, Joon Hyuk Park⁸, Jung Jae Lee⁹, Kyung Phil Kwak¹⁰, Seok Bum Lee⁹, Ki Woong Kim¹¹
¹Department of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ²Department of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ³Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ⁴Department of Neuropsychiatry, Gyeongsang National University Changwon Hospital - Changwon (Korea, Republic of), ⁵Department of Psychiatry, Gyeongsang National University, School of Medicine - Jinju (Korea, Republic of), ⁶Department of Neuropsychiatry, Inje University Sanggye Paik Hospital - Seoul (Korea, Republic of), ⁷Department of Psychiatry, School of Medicine, Chungnam National University - Daejeon (Korea, Republic of), ⁸Department of Neuropsychiatry, Jeju National University Hospital - Jeju (Korea, Republic of), ⁹Department of Psychiatry, Dankook University Hospital - Cheonan (Korea, Republic of), ¹⁰Department of Psychiatry, Dongguk University Gyeongju Hospital - Gyeongju (Korea, Republic of), ¹¹Department of Psychiatry, Seoul National University, College of Medicine - Seoul (Korea, Republic of)
- P199** **Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease in AdventHealth**
Valeria Baldivieso¹, Steven R. Smith¹, Richard E. Pratley¹, Magda Baksh¹, Gayle Shepherd¹, Janice Lopez¹
¹AdventHealth - Orlando (United States)
- P200** **Clinical Management during the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program in Six Countries**
Soeren Matthe¹, Tabasa Ozawa¹, Jiahe Chen¹, Valeria Baldivieso², Otelo Corrêa Dos Santos Filho³, Ishtar Govia⁴, Hisatomo Kowa⁵, Mariana Lopez-Ortega⁶, Alison Mckean⁷, Deanna Willis⁸, Amy Deckert⁹, Katherine Selzler⁹
¹University of Southern California - Los Angeles (United States), ²AdventHealth - Orlando (United States), ³State University of Rio de Janeiro - Rio De Janeiro (Brazil), ⁴Jamaica Mental Health Advocacy Network - Kingston (Jamaica), ⁵Kobe University - Kobe (Japan), ⁶National Institute of Geriatrics - Mexico City (Mexico), ⁷Brain Health Scotland - Edinburgh (United Kingdom), ⁸Indiana University School of Medicine - Indianapolis (United States), ⁹Davos Alzheimer's Collaborative - Wayne (United States)
- P201** **Accounting for Wordlist Feature Differences across Alternate Forms of the ADAS-Cog Word Recall Test**
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, Michael Lee²
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

THEME 7: Behavioral disorders and clinical trials

- P202** **The relationship between neuropsychiatric symptoms and social support among mild behavioral impairment older adults: a moderated mediation model**
Yanhong Shi¹
¹Fujian Medical University - Fuzhou (China)
- P203** **Baseline Demographics of the ECT-AD Trial: Electroconvulsive Therapy for the Management of Treatment-Refractory Agitation and Aggression in Advanced Dementia**
Maria Lapid¹, Martina Mueller², Adriana Hermida³, George Petrides⁴, Louis Nykamp⁵, Anthony Chatham³, David Harper⁶, Simon Kung¹, Sandeep Pagali¹, Regan Patrick⁶, Cristina Pritchett³, Patricio Riva Posse³, Sohag Sanghani⁷, Steve Seiner⁶, Brent Forester⁸
¹Mayo Clinic - Rochester (United States), ²Medical University of South Carolina - Charleston (United States), ³Emory University School of Medicine - Atlanta (United States), ⁴RWJBarnabas Health System, Trinitas Regional Medical Center - Elizabeth (United States), ⁵Pine Rest Christian Mental Health Services - Grand Rapids (United States), ⁶McLean Hospital - Belmont (United States), ⁷Northwell - New Hyde Park (United States), ⁸Tufts University School of Medicine - Boston (United States)
- P204** **Caregiving-related depression increases neuroinflammation in spousal caregivers of individuals with cognitive impairment: a longitudinal study**
So Yeon Jeon¹, Hee Won Yang¹, Jeong Lan Kim¹
¹Chungnam National University Hospital - Daejeon (Korea, Republic of)

POSTER PRESENTATIONS

- P205 Predicting suicide risk in individuals with cognitive decline: integrating sociodemographic and clinical predictors**
 Eva Vidovic ¹, Jernej Rudi Finžgar ², Anja Kokalj Palandacic ¹, Polona Rus Prelog ^{1,3}
¹University Psychiatric Clinic Ljubljana - Ljubljana (Slovenia), ²Technical University Munich, School of CIT, Department of Computer Science - Garching (Germany), ³Faculty of Medicine, University of Ljubljana - Ljubljana (Slovenia)

THEME 8: Health economics and clinical trials

- P206 Risk prediction models of mild cognitive impairment using electronic health record data**
 Gang Li ¹, Viswanath Devanarayan ¹, Rachel Halpern ², Stephane Borentain ¹, Susan Desanti ¹, Jo Vandercappellen ¹, Ara Khachaturian ³, Richard Crisp ², Jeffrey Meyerhoff ², Joanne Bell ¹, Mattke Soeren ⁴, Harald Hampel ¹
¹Eisai - Nutley (United States), ²Optum - Prairie (United States), ³PAD2020 - Washington (United States), ⁴University of Southern California - Los Angeles (United States)
- P207 Development of a simulation model of Alzheimer's Disease to evaluate disease modifying treatments in a memory clinic population**
 Pieter Van Der Veere ^{1,2,3}, Hana Broulikova ^{4,5}, Jeroen Hoogland ⁶, Jort Vijverberg ^{1,3}, Wiesje Flier ^{1,2,3}, Hans Berkhof ²
¹Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), ²Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), ³Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), ⁴Department of Health Science, Faculty of Science, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁵Department of Public Mental Health, National Institute of Mental Health - Klecany (Czech Republic), ⁶Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands) - Amsterdam (Netherlands)
- P208 Estimation of Long-term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea**
 Jun Hong Lee ¹
¹NHIS Ilsan Hospital - Goyang-Si (Korea, Republic of)
- P209 Use of a Mobile Research Unit to Address Health Disparities in Alzheimer's Clinical Trials**
 Santiago Santelis ¹, Sandra Carmona Torres ¹, Rachel Rittichier ¹, Gisel Kautz ¹, Lucy Lenox ¹, Brina Quaning ²
¹K2 Medical Research - Orlando (United States), ²MetroHealth Inc. - Orlando (United States)

THEME 9: Epidemiology and clinical trials

- P210 New-generation antidiabetic drug exposure and dementia risk among older adults with type 2 diabetes: A nationwide cohort study**
 Galit Weinstein ¹
¹School of Public Health, University of Haifa - Haifa (Israel)
- P211 Evaluating ICD-10 Medicare Claims Data as a Method of Identifying Persons Living with Dementia**
 Joya Bhattacharyya ¹, Yi Chen ², Kan Gianattasio ³, Francine Grodstein ³, Bryan James ², Ali Moghtaderi ¹, Christina Prather ¹, David Rein ³, Raj Shah ², Emma Stapp ¹, Melinda Power ⁴
¹George Washington University - Washington, Dc (United States), ²Rush University - Chicago, Il (United States), ³NORC - Chicago, Il (United States), ⁴George Washington University - Washington (United States)
- P212 Use of Medications in Patients with Alzheimer's Disease Before and After Diagnosis**
 Olga Sánchez-Solís ¹, Yael Barer ², Sivan Gazit ², Lisa Vinikoor-Imler ¹, Gabriel Chodick ²
¹AbbVie - North Chicago (United States), ²Maccabi Institute for Research and Innovation, Maccabi Healthcare Services - Tel Aviv (Israel)
- P213 Constructing historic control arms for registry follow-up of anti-amyloid therapies**
 Linus Jönsson ¹
¹Karolinska Institutet - Stockholm (Sweden)
- P214 The Dementia Datahub: Development of a National Surveillance System of Diagnosed Dementia in the United States**
 David Rein ¹, Kan Giannattasio ², John Wittenborn ³, Samuel Knisely ⁴, Bao Carrie ⁴, Gu Qian ⁴, Power Melinda ⁵
¹NORC at the University of Chicago - Atlanta (United States), ²NORC at the University of Chicago - Bethesda (United States), ³NORC at the University of Chicago - Raleigh (United States), ⁴KPMG - Mclean (United States), ⁵KPMG - Washington District Of Columbia (United States)
- P215 Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: A nationwide population-based cohort study**
 Kang Dong Woo ¹
¹Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- P216 Epidemiological Survey of Dementia in the Korean Elderly Population**
 Im Seok Koh ^{1,2}, Jeewon Suh ^{1,2}, Mookyoung Oh ², Jungrea Lee ², Hyunsung Cho ², Se Jin Kim ³
¹Department of Neurology, National Medical Center - Seoul (Korea, Republic of), ²National Institute of Dementia, National Medical Center - Seoul (Korea, Republic of), ³Korea Institute for Health and Social Affairs - Sejong (Korea, Republic of)

POSTER PRESENTATIONS

Poster presentations presented **remotely** are indicated with this icon : 

- P217 **All-cause mortality increased with intracerebral hemorrhage in the United States Medicare Beneficiaries 65 years or older with mild cognitive impairment or Alzheimer's dementia**
Haixin Zhang ¹, Haji Babak ¹, Gao Ran ¹, Irrizary Michael ¹, Zhang Qianwu ¹, Tahami Monfared Amir Abbas ¹
¹Eisai - Nutley (United States)
-  P218 **Relationship Between Hearing Impairment and Dementia and Cognitive Function: A Mendelian Randomization Study**
Deming Jiang ¹, Jiahui Hou ¹, Wu Liyong ¹
¹Department of Neurology, Xuanwu Hospital, Capital Medical University, Changchun Street 45, Beijing, China - Beijing (China)
-  P219 **Epidemiological study of hospital morbidity due to Alzheimer's disease in Brazil from 2008 to 2023: a contribution to clinical trials.**
Julia Fahd ¹, Gabriel Betez ¹, Gustavo Santos ¹, Julia Grilo ¹, Isabelle Borges ¹
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)
-  P220 **The importance of cognitive reserve in maintaining brain health in Alzheimer's disease**
Gabrielle Almeida ¹, Gustavo Santos ², Amanda Scarso ², Beatriz Hara ², Larissa Rubim ², Giovana Villar ², Fabiola Moraes ²
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil), ²Faculdade Sao Leopoldo Mandic de Araras, Medical School - Louveira (Brazil)

THEME 10: Animal model

- P221 **Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration**
Dibyadeep Datta ¹, Isabella Perone ¹, Denethi Wijegunawardana ¹, Feng Liang ², Yuri Morozov ¹, Jon Arellano ¹, Alvaro Duque ¹, Zhongcong Xie ², Christopher Van Dyck ¹, Mary Kate Joyce ¹, Amy Arnsten ¹
¹Yale University - New Haven (United States), ²Massachusetts General Hospital and Harvard Medical School - Boston (United States)
- P222 **2D3A8 a p53 Conformation-Specific Antibody Reacts with Alzheimer's Disease-positive Tissue in human brain samples.**
Shmuel Agus ¹, David Lynch ², Samples Madison ², Rakez Kaye ², Simona Picciarelli ³, Paul Kinnon ³
¹Diadem SpA - Roslindale (United States), ²Mitchell Center for Neurodegenerative diseases, University of Texas Medical Branch (UTMB) - Galveston (United States), ³Diadem Srl - Milano (Italy)
- P223 **Increased Vascular Stiffness in a Genetic Model of Alzheimer's Disease: Effects of the Risk Alleles Independent of Amyloid and Tau Pathology**
Kelly Borges ¹, Meenakshi Yamini Nori ¹, Saud Nasruddin ¹, Olga Savinova ¹
¹New York Institute of Technology College of Osteopathic Medicine - Old Westbury, Ny (United States)
- P224 **Neuronal ACE1 knockout disrupts the hippocampal renin angiotensin system leading to memory impairment and vascular loss**
Leah Cuddy ¹, Sohee Jeon ¹, Miranda Salvo ¹, Jelena Popovic ¹, Mitchell Zagardo ¹, Sidhanth Chandra ¹, Malik Nassan ¹, David Gate ¹, Robert Vassar ¹
¹Northwestern University - Chicago (United States)
- P225 **Cryo-EM Structures of Amyloid- β Fibrils from Alzheimer's Disease Mouse Models**
Fernanda Salome Peralta Reyes ¹, Mara Zielinski ², Lothar Gremer ^{2,3}, Gunnar F. Schröder ^{2,4}
¹Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany), ²Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich - Düsseldorf (Germany), ³Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany) - Düsseldorf (Germany), ⁴Physics Department, Heinrich Heine University Düsseldorf - Düsseldorf (Germany)

THEME 13: Digital health/E-trials

- P226 **Retinal AI-based Alzheimer's Disease Detection Model Identifies Poor Brain Health in Cognitively Unimpaired Subjects**
Vincent Chung Tong Mok ¹, Ho Ko ¹, Bonnie Yin Ka Lam ¹, Huijing Zheng ¹, Yuen Ting Ng ¹, Lisa Wing Chi Au ¹, Alex Yuk Lun Lau ¹, Alan Hiu Fung Lam ², Anran Ran ³, Xiaoyan Hu ³, Ha Ying Chiu ⁴, Carol Yim Lui Cheung ³
¹Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ²Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ³Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ⁴The Charles Kao Foundation for Alzheimer's Disease - Hong Kong (Hong Kong)
- P227 **Cognitive therapy software for improving cognitive function for patients with MCI**
Hojin Choi ¹, Jong Hyun Jeon ¹, Yangki Minn ², Chi Kyung Kim ³
¹Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), ²Department of Neurology, Kangnam Sacred Heart Hospital - Seoul (Korea, Republic of), ³Department of Neurology, Korea University Guro Hospital - Seoul (Korea, Republic of)
- P228 **Cognitive Rehabilitation Programs for Older Adults using Digital Voice Assistants**
Paul Jansons ¹, Helen Macpherson ¹, David Scott ¹, Tracy Yiannis ¹
¹Deakin University - Burwood (Australia)

- P229 Earlier is better: Clinical Trial Simulator SimulAD quantifies the relationship between amyloid/tau load severity and the amplitude of cognitive benefits of anti-amyloid treatments.**
Anna Custo^{1,2}, Marco Lorenzi³, Giovanni Frisoni⁴, Valentina Garibotto^{1,2,5}
¹Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University - Geneva (Switzerland), ²Neurocenter and Faculty of Medicine, University of Geneva - Geneva (Switzerland), ³Inria Sophia Antipolis, Université Côte d'Azur - Sophia Antipolis (France), ⁴Geneva Memory Center, Geneva University Hospitals and Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland), ⁵Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and CIBM Center for Biomedical Imaging, Geneva University Hospitals - Geneva (Switzerland)
- P231 Digital Assessment of Cognition for Optimizing Neuropsychology Workflow**
 Ali Jannati¹, Karl Thompson¹, Claudio Toro-Serey¹, Russell Banks¹, Connor Higgins¹, Jeff Pobst¹, John Showalter¹, David Bates¹, Sean Tobyne¹, David Libon¹, Rod Swenson¹, Alvaro Pascual-Leone¹
¹Linus Health - Boston (United States)
- P232 Comparing Eye-Tracking Metrics for Figure-Copying in Amyloid-Negative and Amyloid-Positive Mild Cognitive Impairment**
Ko Woon Kim¹, Qi Wang², Su Jeong Wang³, Byoung-Soo Shin¹
¹Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), ²Jeonbuk National University Medical School - Jeonju (Korea, Republic of), ³Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
- P233 Validation of a Lifestyle Risk Assessment 'Smart Tracker' tool**
Larissa Mcketton¹, Angela Troyer^{2,3}, Nicole Anderson^{1,3,4}
¹Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), ²Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), ³Department of Psychology, University of Toronto - Toronto (Canada), ⁴Department of Psychiatry, University of Toronto - Toronto (Canada)
- P234 Agreement between Altoida's Digital Biomarker Platform and standard neuropsychological tests in individuals with subjective memory complaints**
M. Florencia Iulita¹, Alberto Ferrari¹, Gonzalo Sanchez Benavides², Victoria Brugada Ramentol¹, Silvia Fallone¹, Nicholas Griffin¹, Emmanuel Streef¹, Oriol Grau-Rivera², Carolina Minguillon², Claudia Porta-Mas², Mylea Charvat¹, Ioannis Tarnanas¹
¹Altoida Inc. - Washington Dc (United States), ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain)
- P235 Reliability and validity of a tablet-based neuropsychological test (the HelloCog) for screening dementia**
Hee Won Yang¹, Daniel Hahnsam Seok², Ki Woong Kim²
¹Chungnam national university hospital - Daejeon (Korea, Republic of), ²Seoul National University - Seoul (Korea, Republic of)
- P236 Virtual reality-based cognitive training improves cognitive function in alzheimer's disease patients**
Ho-Won Lee¹, Dohun Kim²
¹Dep. of Neurology, School of Medicine, Kyungpook National University - Daegu (Korea, Republic of), ²G-L Co, Ltd - Daegu (Korea, Republic of)
- P237 The effectiveness of a virtual reality-based cognitive training program for mild cognitive impairment: A pilot study**
Eek-Sung Lee¹, Seung-Keun Lee¹, Tae-Kyeong Lee¹, Seuonghee Na², Yang Ho Kim³
¹Soonchunhyang University Bucheon Hospital - Bucheon (Korea, Republic of), ²Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea - Incheon (Korea, Republic of), ³Tenetus Co. - Seoul (Korea, Republic of)
- P238 Memory features obtained through automated phone calls associate to the intensity of subjective cognitive decline in cognitively unimpaired individuals**
Clàudia Porta-Mas^{1,2}, Gonzalo Sánchez-Benavides^{1,2,3}, Elisa Mallick⁴, Johannes Tröger⁴, Nicklas Linz⁴, Alexandra König⁴, Andreea Radoi¹, Carlota Medina¹, Alba Cañas-Martínez¹, Anna Brugulat-Serrat¹, Lidia Canals-Gispert¹, Isabel Pérez-Gutiérrez¹, Marc Suárez-Calvet^{1,2,3,5}, Juan Domingo Gispert^{1,2,3}, Oriol Grau-Rivera^{1,2,3,5}
¹BarcelonaBeta Brain Research Center - Barcelona (Spain), ²Hospital del Mar Research Institute (IMIM) - Barcelona (Spain), ³Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), ⁴ki-elements - Saarbrücken (Germany), ⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain)
- P239 Quantifying Prediction Confidence in AI Models for EEG Analysis**
Mats Tveter^{1,2}, Thomas Tveitstøl^{1,2}, Ana Perez^{1,2}, Christoffer Hatlestad-Hall¹, Hanna Renvall^{3,4}, Fernando Maestú^{5,6,7}, Camillo Marra^{8,9}, Paolo Maria Rossini¹⁰, Ira R. J. Hebold Haraldsen¹
¹Oslo University Hospital - Oslo (Norway), ²Faculty of Medicine, University of Oslo - Oslo (Norway), ³Aalto University - Helsinki (Finland), ⁴BioMag Laboratory, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁵Universidad Complutense de Madrid - Madrid (Spain), ⁶Department of Experimental Psychology, Universidad Complutense de Madrid - Madrid (Spain), ⁷IdiSSC, San Carlos University Hospital - Madrid (Spain), ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁹Catholic University of the Sacred Heart - Rome (Italy), ¹⁰IRCCS San Raffaele - Rome (Italy)
- P240 Self-supervised learning for feature extraction in EEG**
Thomas Tveitstøl^{1,2}, Mats Tveter^{1,2}, Christoffer Hatlestad-Hall¹, Camillo Marra^{3,4}, Hanna Renvall^{5,6}, Fernando Maestú^{7,8,9}, Paolo Maria Rossini¹⁰, Ira R. J. Hebold Haraldsen¹
¹Oslo University Hospital - Oslo (Norway), ²Faculty of Medicine, University of Oslo - Oslo (Norway), ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁴Catholic University of the Sacred Heart - Rome (Italy), ⁵Aalto University - Helsinki (Finland), ⁶BioMag Laboratory, Helsinki University and Aalto University - Helsinki (Finland), ⁷Universidad Complutense de Madrid - Madrid (Spain), ⁸Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), ⁹IdiSSC, San Carlos University Hospital - Madrid (Spain), ¹⁰IRCCS San Raffaele - Rome (Italy)

- P241 All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**
Ying Wang ^{1,2}, Peter Morin ^{3,2}, Vanesa Arasa ^{3,4}, Brant Mittler ⁵, Joel Reisman ^{2,6}, Raymond Zhang ⁷, Amir Abbas Tahami Monfared ^{7,8}, Quanwu Zhang ⁷, Weiming Xia ^{2,6,3}
¹Wentworth Institute of Technology - Boston (United States), ²VA Bedford Healthcare System - Bedford (United States), ³Boston University - Boston (United States), ⁴VA Boston Healthcare System - Boston (United States), ⁵VA South Texas Healthcare System - San Antonio (United States), ⁶University of Massachusetts - Lowell (United States), ⁷Eisai, Inc - Nutley (United States), ⁸McGill University - Montreal (Canada)
- P242 All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced seizure**
Myriam Abdennadher ¹, Ying Wang ^{2,3}, Peter Morin ^{1,3}, Vanesa Arasa ^{1,4}, Brant Mittler ⁵, Joel Reisman ^{3,6}, Raymond Zhang ⁷, Amir Abbas Tahami Monfared ^{7,8}, Michale Irizarry ⁷, Quanwu Zhang ⁷, Weiming Xia ^{3,6,1}
¹Boston University - Boston (United States), ²Wentworth Institute of Technology - Boston (United States), ³VA Bedford Healthcare System - Bedford (United States), ⁴VA Boston Healthcare System - Boston (United States), ⁵VA South Texas Healthcare System - San Antonio (United States), ⁶University of Massachusetts - Lowell (United States), ⁷Eisai, Inc - Nutley (United States), ⁸McGill University - Montreal (Canada)
- P243 Home-based brain monitorization with a self-management EEG to study cognitive decline in ageing population (HOGAR study)**
Esperanza Jubera Garcia ¹
¹Bitbrain - Zaragoza (Spain)
- P244 Seizure in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**
Myriam Abdennadher ^{1,2}, Ying Wang ^{3,4}, Peter J Morin ⁴, Vanesa Carlota Andreu Arasa ^{5,6}, Brant Mittler ⁷, Joel Reisman ^{8,9}, Zhang Raymond ¹⁰, Amir Abbas Tahami Monfared ^{10,11}, Michael Irizarry ¹⁰, Quanwu Zhang ¹⁰, Weiming Xia ^{9,12,13}
¹Boston Medical Center - Boston (United States), ²Boston University Chobanian & Avedisian School of Medicine - Boston (United States), ³Wentworth Institute of Technology - Boston (United States), ⁴Research Service, VA Bedford Healthcare System - Bedford (United States), ⁵Neuroradiology, VA Boston Healthcare system - Boston (United States), ⁶Radiology, Boston Chobanian & Avedisian School of Medicine - Boston (United States), ⁷Geriatric Research Education & Clinical Center, VA South Texas Healthcare System - San Antonio (United States), ⁸Center for Healthcare Organization & Implementation, VA Bedford Healthcare System - Bedford (United States), ⁹Department of Biological Sciences, University of Massachusetts Lowell - Lowell (United States), ¹⁰Alzheimer's Disease & Brain Health, Eisai Inc. - Nutley (United States), ¹¹McGill University - Montreal (Canada), ¹²Geriatric Research Education and Clinical Center - Bedford, (United States), ¹³Pharmacology, Physiology and Biophysics, Boston University Chobanian & Avedisian School of Medicine - Boston (United States)
-  **P245 Big Data from Smart Ecosystems Targeting Cognitive Impairment**
Razvan Ioan Trasca ^{1,2}, Mircea Dan Marzan ^{1,2}, Luiza Spiru ^{1,2}
¹"Carol Davila" University of Medicine and Pharmacy - Bucharest (Romania), ²Ana Aslan International Foundation - Bucharest (Romania)
-  **P246 MRI imaging biomarker prediction using Alzheimer's disease characteristic acoustic speech features**
Seonki Chung ¹, Hyunsun Ham ², Minju Bae ², Hyeonjin Kim ², Keun You Kim ², Jun-Young Lee ^{2,1}
¹Seoul National University College of Medicine - Seoul (Korea, Republic of), ²SMG-SNU Boramae Medical Center, Department of Psychiatry - Seoul (Korea, Republic of)
-  **P247 ReMember-Me: Enhancing Cognitive Health in Older Adults Through Daily Activities and Social Engagement**
Andreea Stamate ¹
¹Ana Aslan International Foundation - Bucharest (Romania)
-  **P248 Analysis of Connectivity in AI-Mind Data using Graph Neural Networks**
Mohamed Radwan ¹, Pedro G. Lind ¹, Rabindra Khadka ¹, Asma Belhadi ¹, Ira Haraldsen ², Paolo Rossini ³, Camillo Marra ⁴, Fernando Maestu ⁵, Hanna Renvall ⁶, Erik Christensen ⁷, Anis Yazidi ¹
¹Oslo Metropolitan University - Oslo (Norway), ²Oslo University Hospital - Oslo (Norway), ³Università Cattolica del Sacro Cuore - Milan (Italy), ⁴IRCCS San Raffaele Pisana - Rome (Italy), ⁵Universidad Politécnica de Madrid - Madrid (Spain), ⁶Helsinki University Hospital - Helsinki (Finland), ⁷Pre Diagnostics AS - Oslo (Norway)
-  **P249 EEG-JEPA: Self-Supervised Learning from EEG Signals with a Joint-Embedding Predictive Architecture**
Rabindra Khadka ¹, Pedro G. Lind ^{1,2}, Christoffer Hatlestand-Hall ³, Mohamed Radwan ¹, Asma Belhadi ¹, Gustavo Mello ¹, Michael A. Riegler ^{1,4}, Erik Christensen ⁵, Hanna Renvall ^{6,7}, Fernando Maestu ^{8,9}, Camillo Marra ^{10,11}, Paolo M. Rossini ¹², Ira H. Haraldsen ³, Anis Yazidi ¹
¹Oslo Metropolitan University - Oslo (Norway), ²Simula - Oslo (Norway), ³University of Oslo - Oslo (Norway), ⁴Simulamet - Oslo (Norway), ⁵Pre Diagnostics AS - Oslo (Norway), ⁶Aalto University, Helsinki, Finland - Helsinki (Finland), ⁷Helsinki University Hospital - Helsinki (Finland), ⁸Universidad Complutense de Madrid - Madrid (Spain), ⁹San Carlos University Hospital - Madrid (Spain), ¹⁰Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ¹¹Catholic University of the Sacred Heart - Rome (Italy), ¹²Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)

POSTER PRESENTATIONS

THEME 15: Clinical Trials Early Career Investigator Showcase

- P250 **The risk factors affecting CDR-SOB changes in amyloid-beta negative individuals with mild cognitive impairment and subjective memory impairment**
Hyunji Lee¹
¹*Pusan National Univalsty Hospital - Busan (Korea, Republic of)*
- P251 **Association of Alzheimer's disease biomarkers and emotional states: analysis of individuals with and without preclinical Alzheimer's disease in the A4 trial**
Taimur Kouser¹, James Kelbert², Ingrid Luo¹, Zihuai He³, Irina Skylar-Scott¹
¹*Stanford University - Palo Alto (United States)*, ²*University of Arizona - Phoenix (United States)*, ³*University of Arizona - Palo Alto (United States)*
- P252 **Changes in cognitive and neural markers of Alzheimer's disease in response to aerobic and non-aerobic exercise among cognitively healthy older African Americans: The role of body composition, genetics, and sex**
Bernadette Fausto¹
¹*Rutgers-The State University of New Jersey - Newark (United States)*
- P253 **Association between cognitive performance and emotional states: analysis from the A4 trial**
James Kelbert¹, Taimur Kouser², Ingrid Luo², Christina Young², Zihuai He², Irina Skylar-Scott²
¹*University of Arizona - Phoenix*, ²*Stanford University - Palo Alto (United States)*



CTAD 2024 VENUE

Madrid Marriott Auditorium Hotel & Conference Center

Avda de Aragon 400 - 8022 Madrid, SPAIN



The conference hotel is sold out, for hotels nearby
check out our accommodations page
at www.ctad-alzheimer.com



CTAD 2024

Clinical Trials on Alzheimer's Disease

> LATE CALL FOR ABSTRACTS
opens: August 12
Deadline to submit September 10

Follow us on social media!



@CTADConference
#CTAD24



CTAD Conference



CTAD Alzheimer

CTAD Congress > Email: ctad@ant-congres.com
www.ctad-alzheimer.com